Presenting Complaints

Obstructive Jaundice

Obstructive jaundice is a condition caused by blockage of the bile ducts, preventing bile drainage into the intestine and resulting in conjugated hyperbilirubinemia, dark urine, pale stools, and pruritus.

Obstructive jaundice — also called post-hepatic jaundice or surgical jaundice — is the clinical syndrome resulting from impaired drainage of bile from the intrahepatic bile canaliculi through the biliary tree into the duodenum. The obstruction causes conjugated (direct) bilirubin to accumulate in the blood, producing the classic triad of yellow discolouration of skin and sclerae, pale (clay-coloured) stools, and tea-coloured (dark) urine [1][2].

Let's break the term down:

  • Obstructive = a physical or functional blockage preventing normal flow
  • Jaundice (from French jaunisse, meaning "yellowness") = yellow pigmentation of skin and mucous membranes due to elevated bilirubin; clinically detectable when serum bilirubin ≥ 2× ULN (~40–50 µmol/L) [2][3]

Painless progressive obstructive jaundice in an elderly patient is malignant biliary obstruction until proven otherwise [1][3][4].

Key Distinction

Obstructive jaundice is fundamentally a conjugated hyperbilirubinaemia — the liver can conjugate bilirubin just fine, but conjugated bilirubin cannot reach the gut. This distinguishes it from pre-hepatic (unconjugated) and most hepatocellular causes.


Epidemiology and Risk Factors

ParameterDetail
Gallstone-related obstructionMost common benign cause worldwide and in HK. Choledocholithiasis accounts for the majority of obstructive jaundice presentations to the Emergency Department.
Pancreatic carcinoma6th overall for cancer mortality in HK (incidence 9.2/100,000/year); median age 65 y, M:F ≈ 1.3:1 [5]
Cholangiocarcinoma3% of all GI malignancies, 5–20% of primary liver malignancies; incidence 1–2/100,000 in the West but higher in SE Asia (parasitic infections); median age 65 y [6]
Recurrent pyogenic cholangitis (RPC)Historically prevalent in southern China/HK due to liver flukes (Clonorchis sinensis); declining but still encountered [7]
Gallbladder carcinomaVery rare in HK, more common in women; extremely poor prognosis (5-year OS < 5%) [7]

For gallstone-related obstruction (benign):

  • Classic "Fat, Female, Fertile, Forty" — risk factors for cholesterol gallstones [2]
  • Obesity, rapid weight loss, metabolic syndrome, oestrogen (OCP, pregnancy), ileal disease (Crohn's), TPN

For malignant biliary obstruction:

Risk FactorMechanism / Notes
Primary sclerosing cholangitis (PSC)Chronic inflammation → fibrosis/stricturing of bile ducts; lifetime cholangiocarcinoma risk 5–15%; strongly associated with ulcerative colitis [6][7]
Cholelithiasis / HepatolithiasisChronic intrahepatic stones → biliary stasis → recurrent pyogenic cholangitis → chronic inflammation → malignant transformation [7]
Parasitic infection (Clonorchis sinensis, Opisthorchis viverrini)Ingestion of undercooked freshwater fish → adult flukes inhabit biliary tree → chronic inflammation → malignant transformation of ductal epithelium [6][7]
Fibrocystic liver disease (choledochal cysts, Caroli's disease)Biliary stasis + reflux of pancreatic juice + abnormal bile salt transporters → chronic inflammation → cholangiocarcinoma [7]
Chronic liver disease (HBV, HCV, cirrhosis, alcohol)10× risk for intrahepatic cholangiocarcinoma [6]
Smoking1.5× risk for pancreatic CA; most important modifiable risk factor [5]
Diabetes mellitus, obesity, metabolic syndromePromote pancreatic and biliary carcinogenesis [5][7]
Genetic syndromesLynch syndrome (MMR gene mutations), hereditary pancreatitis (PRSS1, SPINK1), BRCA1/2, Peutz-Jeghers (STK11), FAMMM (CDKN2A) [5][6]
Familial pancreatic CA≥1 first-degree relative: 4.6×; ≥2: 6.4×; ≥3: 32× [5]
Non-O blood group, male gender, advanced age, African-American raceEpidemiological associations for pancreatic CA [5]

Anatomy and Function of the Biliary System

Understanding obstructive jaundice is impossible without a firm grasp of biliary anatomy. Think of the biliary tree as a plumbing system that drains bile from liver to gut.

  • Bile produced by hepatocytes drains into bile canaliculi → interlobular (portal) bile ductules → progressively larger intrahepatic ducts → right and left hepatic ducts.

  1. Right hepatic duct (RHD) + Left hepatic duct (LHD) converge at the hepatic hilum (confluence) → Common hepatic duct (CHD) [1][7]
  2. Cystic duct (from the gallbladder neck/Hartmann's pouch) joins the CHD → Common bile duct (CBD), typically ~6–8 mm in diameter (≤8 mm is normal; post-cholecystectomy up to 10–11 mm is acceptable)
  3. CBD passes behind the first part of the duodenum and through the head of the pancreas
  4. CBD joins the main pancreatic duct (duct of Wirsung) → hepatopancreatic ampulla (ampulla of Vater) → opens at the major duodenal papilla into the second part of the duodenum
  5. The sphincter of Oddi is a muscular valve surrounding the ampulla, regulating bile and pancreatic juice flow

  • Located in the gallbladder fossa on the undersurface of liver segments IV and V
  • Composed of fundus, body, infundibulum (Hartmann's pouch), and neck [7]
  • Functions: concentrates and stores bile between meals; contracts in response to CCK released post-prandially

  • Bile is essential for emulsification and absorption of dietary fats and fat-soluble vitamins (A, D, E, K)
  • Bile also serves as the excretory route for conjugated bilirubin, cholesterol, drugs, and toxins
  • Normal barrier mechanisms of the biliary tree prevent infection: continuous flushing action of bile, bacteriostatic bile salts, biliary mucous IgA, and the sphincter of Oddi as a mechanical anti-reflux barrier [7]

Clinical Pearl — Why the Level of Obstruction Matters

The biliary tree can be divided into three surgical segments for differential diagnosis:

  • Hilum (confluence): Klatskin tumour, CA gallbladder, HCC, Mirizzi syndrome, porta hepatis lymphadenopathy, PSC, RPC
  • Mid-CBD: cholangiocarcinoma of CBD, CA head of pancreas, lymphadenopathy
  • Distal CBD: bile duct strictures, periampullary carcinoma, choledochal cysts, pancreatic cysts, chronic pancreatitis [1]

The level determines which parts of the biliary tree are dilated on imaging — this is your first clue.


Bilirubin Metabolism — First Principles

To understand why obstructive jaundice produces the symptoms it does, you need to trace bilirubin from cradle to grave:

When the bile duct is blocked:

  1. Conjugated bilirubin cannot enter the gut → it regurgitates back into blood → conjugated hyperbilirubinaemia
  2. Conjugated bilirubin is water-soluble → filtered by kidneys → tea-coloured urine [2][3]
  3. No bilirubin reaches the colon → no bacterial conversion to stercobilinogen/stercobilin → pale/clay-coloured stools [1][2]
  4. No urobilinogen formed in the gut → urinary urobilinogen is absent (distinguishes complete obstruction from hepatocellular jaundice, where urinary urobilinogen is actually increased) [7]
  5. Bile salts accumulate in blood → deposit in skin → stimulate sensory nerve endings → generalised pruritus [2][3]
  6. No bile salts in gut → impaired fat emulsification → fat malabsorption → steatorrhoea (floating, foul-smelling, difficult to flush) and malabsorption of fat-soluble vitamins (A, D, E, K) [1]

Etiology (Hong Kong Focus)

The differential diagnosis of extrahepatic obstruction is organised as intraluminal, mural, and extramural [2][3]:

LocationBenignMalignant
IntraluminalCBD stones (most common overall); cholangitis / RPC; parasites (Ascaris lumbricoides, liver flukes — Clonorchis sinensis); haemobilia (very rare)Tumour thrombus (rare, in HCC)
MuralBenign strictures (post-instrumentation, gallstones, chronic pancreatitis); PSC; Sphincter of Oddi dysfunction (intermittent)Cholangiocarcinoma (hilar / CBD)
ExtramuralMirizzi syndrome; acute/chronic pancreatitis; choledochal cystsCarcinoma of head of pancreas; Carcinoma of ampulla of Vater or duodenum; Porta hepatis lymphadenopathy (from CA stomach, gallbladder, HCC, lymphoma)

Intrahepatic causes of cholestasis (not strictly "obstructive" but present similarly) [2][3]:

  • Hepatocyte dysfunction (hepatitis, end-stage liver disease)
  • Drugs (anabolic steroids, OCP, chlorpromazine, arsenic)
  • Primary biliary cholangitis (autoimmune destruction of small ducts)
  • No enteric intake / TPN (↓CCK → ↓GB contraction)
  • Intrahepatic cholestasis of pregnancy (associated with ↑oestrogen)
  • Massive liver SOL compressing bilateral bile ducts (very uncommon)

Major Causes — Detailed Pathophysiology

Gallstones form in the gallbladder (cholesterol stones in the West, pigment stones more common in Asia) and can migrate through the cystic duct into the CBD. A stone impacted at the distal CBD/ampulla causes mechanical obstruction to bile flow.

  • Pathophysiology: ↑biliary pressure proximal to stone → bile stasis → conjugated bilirubin regurgitates into blood → jaundice; if bacteria contaminate the stagnant bile → ascending cholangitis
  • Usually presents with episodic, painful jaundice in younger individuals with a history of gallstone disease [2][3]

Ductal adenocarcinoma accounts for ~85–90% of pancreatic cancers. 60% arise in the head of the pancreas [4][5].

  • Pathophysiology: tumour in the pancreatic head encases or compresses the intrapancreatic portion of the CBD → progressive, complete obstruction → painless, progressive jaundice
  • Head tumours present earlier (due to jaundice) and have a relatively better prognosis than body/tail tumours (which present late with pain and metastases) [4][5]
  • Double duct sign on imaging: simultaneous dilatation of both the pancreatic duct and CBD, suggesting a mass at their confluence [4]

Tumour of the ductular epithelium (cholangiocytes) of intra- or extrahepatic bile ducts. "Cholangio" = bile duct, "carcinoma" = malignant epithelial tumour.

  • Sites: intrahepatic ( < 10%), perihilar (Klatskin tumour, ~50%), distal (~40%) [6]
  • Perihilar tumours classified by Bismuth-Corlette: Type I (below confluence), II (reaching confluence), IIIa/b (involve CHD + R/L hepatic duct), IV (multicentric or involve both RHD and LHD) [6]
  • Pathophysiology: slow-growing but locally invasive tumour causes progressive narrowing → complete obstruction of bile duct → obstructive jaundice
  • Pathology: adenocarcinoma (> 90%); sclerosing (majority), papillary, nodular variants; characterised by slow growth but early local invasion with marked desmoplastic (fibrotic) stromal reaction [6]

A group of tumours arising in the region of the ampulla of Vater, including:

  • Carcinoma of the ampulla of Vater
  • Carcinoma of the duodenum (periampullary segment)
  • Distal cholangiocarcinoma
  • Carcinoma of head of pancreas

These all cause distal CBD obstruction and present similarly.

  • A large gallstone impacted in the cystic duct or Hartmann's pouch extrinsically compresses the adjacent common hepatic duct, causing obstructive jaundice [7]
  • Pathophysiology: the cystic duct runs parallel and close to the CHD. A large impacted stone → direct mechanical compression + secondary inflammation → CHD obstruction. Chronic inflammation may cause cholecystobiliary fistula (erosion of the stone into the CBD) [7]
  • Classified as extramural obstruction despite being a gallstone disease

  • Also called "oriental cholangiohepatitis"; historically common in southern China/HK
  • Characterised by primary intrahepatic (pigment) stones → recurrent bouts of bacterial cholangitis → progressive biliary stricturing
  • Associated with Clonorchis sinensis infection in endemic areas [6][7]
  • Important exception to Courvoisier's law (see below)

  • Chronic progressive cholestatic disease: inflammation, fibrosis, and stricturing of medium and large intra-/extrahepatic bile ducts [8]
  • Characteristically occurs in young men (70% men, 25–40 y) [8]
  • Strongly associated with ulcerative colitis (2/3 of PSC patients have UC) [8]
  • Characteristic "beaded" appearance on cholangiography (alternating strictures and dilatations)
  • Risk of cholangiocarcinoma: lifetime risk 5–15%

Per Prof R Poon's lecture [9]:

  • Hepatomegaly secondary to biliary obstruction
  • Hepatomegaly due to metastases or HCC
  • Lymph node metastases to the coeliac axis or porta hepatis
  • Carcinoma of stomach with metastatic lymph node in the porta hepatis
  • Distended stomach due to duodenal obstruction by tumour which obstructs the bile duct as well

Pathophysiology of Obstructive Jaundice — Systemic Consequences

Obstructive jaundice is not just "yellow skin" — it triggers a cascade of pathophysiological disturbances that increase operative risk and must be understood for management.

Key pathophysiological disturbances due to malignant biliary obstruction (MBO) [1][9]:

  • Why? Bile salts are needed in the gut to emulsify fats → absorb fat-soluble vitamin K → vitamin K is a cofactor for hepatic synthesis of clotting factors II, VII, IX, X (and proteins C and S)
  • In obstruction: no bile in gut → vitamin K malabsorption → deficiency of vitamin K-dependent clotting factors → coagulopathy [1]
  • Impaired clotting factor synthesis also occurs in prolonged obstruction as the liver parenchyma suffers from cholestasis-induced damage [1]
  • Clinical relevance: must correct coagulopathy (give IV/IM vitamin K) before any invasive procedure (ERCP, PTC, surgery)

  • Why? The liver's Kupffer cells (part of the reticuloendothelial system) normally clear portal-venous endotoxins absorbed from the gut. In obstructive jaundice:
    • Endotoxaemia occurs because the liver is unable to defend against gut endotoxins [1]
    • Impaired reticuloendothelial function [1]
    • Impaired cell-mediated immunity [1]
    • Absent bile salts in gut → bacterial overgrowth → increased translocation
  • Patients with MBO are at significantly increased risk of post-operative sepsis

  • Why? Impaired protein synthesis by the cholestatic liver → inadequate collagen deposition and tissue repair [1]
  • Nutrition is also impaired (fat malabsorption, anorexia from malignancy)

  • Bile salts and bilirubin are directly nephrotoxic
  • Endotoxaemia promotes renal vasoconstriction
  • Dehydration from anorexia/vomiting
  • Clinical relevance: adequate hydration and careful monitoring of renal function peri-operatively

  • Prolonged cholestasis → secondary biliary cirrhosis (if chronic)
  • Cholestasis impairs hepatocyte function → reduced drug metabolism, reduced synthetic function
  • Effect on liver function is slow in onset [3] — this is why drainage can sometimes wait for proper imaging

Classification

  1. Mechanical obstruction (majority): physical blockage by stone, tumour, stricture
  2. Functional obstruction: sphincter of Oddi dysfunction (intermittent, no structural lesion)

  1. Benign: gallstones, benign strictures, chronic pancreatitis, choledochal cysts, PSC, Mirizzi syndrome, parasites
  2. Malignant: CA head of pancreas, cholangiocarcinoma, CA ampulla of Vater, CA duodenum, CA gallbladder, metastatic lymphadenopathy

LevelCauses
HilumKlatskin tumour, CA gallbladder, HCC, Mirizzi syndrome, porta hepatis lymphadenopathy, PSC, RPC [1]
Mid-CBDCholangiocarcinoma of CBD, CA head of pancreas, lymphadenopathy [1]
Distal CBDCBD stones, benign strictures, periampullary carcinoma, choledochal cysts, pancreatic cysts, chronic pancreatitis [1]

TypeDescription
IBelow the confluence of L/R hepatic ducts
IIReaching the confluence
IIIaInvolve CHD and RHD
IIIbInvolve CHD and LHD
IVInvolve CHD, RHD and LHD / Multicentric

Clinical Features

This is the single most important clinical question when you see obstructive jaundice. The lecture slides and senior notes emphasise this distinction [2][3]:

FeatureStone (Benign)Tumour (Malignant)
AgeYoungerOlder (> 60 y)
OnsetEpisodic, suddenGradual, progressive
PainRUQ pain / biliary colic (painful jaundice)Painless (until late — CA pancreas may have dull, boring epigastric pain radiating to back)
FeverCommon (cholangitis)Uncommon initially
Jaundice patternFluctuating (may resolve when stone passes)Progressive, deepening
StoolMay improve intermittentlyPersistently pale
Weight lossMinimalSignificant (constitutional symptoms)
GallbladderUsually NOT palpable (Courvoisier's law)Palpable, non-tender
HistoryPrevious biliary colic, known gallstonesNew onset, no prior biliary Hx

Symptoms (with Pathophysiological Basis)

  • Mechanism: Conjugated bilirubin cannot be excreted → regurgitates into blood → deposits in tissues with high elastin content (sclera first, then skin)
  • Sclera turns yellow first because bilirubin has high affinity for elastin, which is abundant in scleral tissue
  • Obstructive jaundice classically has a greenish tinge (due to oxidation of bilirubin to biliverdin in prolonged obstruction) as opposed to the "lemon-yellow" of haemolysis [2][3]
  • Clinically detectable at bilirubin ≥ 2× ULN (~40–50 µmol/L) [3]

  • Mechanism: Conjugated bilirubin is water-soluble → freely filtered by glomeruli → excreted in urine → dark "tea-coloured" or "Pu-erh tea" (普洱茶咁深色) coloured urine [2][3]
  • This is one of the earliest signs — often precedes visible jaundice
  • Important to ask: "Have you recently taken rifampicin, Pyridium, or beetroot?" (these can also darken urine) [2]

  • Mechanism: No conjugated bilirubin reaches the colon → no bacterial deconjugation to stercobilinogen/stercobilin (the pigment that gives stool its brown colour) → pale, clay-coloured stools [1][2]
  • Persistent acholic stools suggest complete obstruction (malignant); intermittent suggests incomplete/ball-valve obstruction (stone)

  • Mechanism: No bile salts in the gut → impaired fat emulsification → fat malabsorption → floating, foul-smelling stools that are difficult to flush [2]
  • Patients may describe "oily" stools

  • Mechanism: Bile salts (and possibly other pruritogens like lysophosphatidic acid and autotaxin) accumulate in blood → deposit in skin → stimulate cutaneous sensory nerve endings and itch receptors → generalised pruritus, often worse at night
  • May present with scratch marks (excoriations) on examination
  • Non-specific and not always reliable as a diagnostic feature [3]

  • Biliary colic (stone): sudden onset, severe, constant (despite being called "colic"), RUQ or epigastric, lasts 30 min to 6 hours, may radiate to right scapula
  • Severe epigastric pain radiating to the back (CA body/tail of pancreas): retroperitoneal infiltration of the coeliac plexus [4]
  • Painless jaundice: the hallmark of malignant biliary obstruction — tumours grow slowly and progressively obstruct without acute inflammatory changes

  • Loss of appetite (LOA), loss of weight (LOW), malaise [2][3]
  • Mechanism: tumour-related cytokines (TNF-α, IL-6), cancer cachexia, malabsorption
  • New-onset diabetes mellitus in an elderly patient with jaundice is highly suspicious of pancreatic CA (tumour destroys islets) [4]

  • Steatorrhoea, maldigestion, malabsorption, new-onset DM — because the tumour may obstruct the pancreatic duct or destroy pancreatic parenchyma [4]

  • Bone pain, dyspnoea (lung mets), neck lump (Virchow's node / left supraclavicular LN) [3]

Signs (with Pathophysiological Basis)

  • Jaundice: inspect mucous membranes of sclera, mouth, palms and soles under natural light (protected from sun → minimises photodegradation of bilirubin) [2][3]
  • Cachexia / wasting: suggests malignancy (cancer cachexia)
  • Scratch marks (excoriations): from pruritus due to bile salt deposition in skin
  • Pallor: may suggest anaemia (chronic disease, GI blood loss from ampullary tumour)
  • Greenish jaundice: prolonged obstructive jaundice → bilirubin oxidised to biliverdin [2]

"In painless jaundice, if the gallbladder is palpable, the cause is unlikely to be due to gallstones" — this points towards malignant biliary obstruction [1][2][7].

Pathophysiological basis [1][7]:

  • Gallstones develop chronically → repeated bouts of cholecystitis → gallbladder wall becomes fibrosed and contracted → it simply cannot distend even when the CBD is obstructed
  • Malignant obstruction develops acutely (relative to the gallbladder's history) in a previously normal, compliant gallbladder → back-pressure from CBD obstruction → gallbladder distends and becomes palpable
  • On palpation: smooth, non-tender, globular mass in the RUQ that moves with respiration

Exceptions to Courvoisier's Law

Students often forget the exceptions:

  1. Double impaction (~7%) — one stone in the CBD (causing jaundice) + another in the cystic duct (causing mucocele → gallbladder distension even in a fibrotic gallbladder) [7]
  2. Mirizzi syndrome — the essential pathology is extrinsic compression of CHD by a cystic duct/Hartmann's pouch stone, not chronic cholecystitis of the gallbladder wall itself [7]
  3. Recurrent pyogenic cholangitis (RPC) — the primary pathology is in the bile ducts, not the gallbladder → the gallbladder has not undergone chronic cholecystitis → it can still distend [1][7]

  • Mechanism: biliary back-pressure → distension of intrahepatic bile ducts → liver swells; or hepatic metastases (nodular, hard, irregular edge); or HCC in the setting of CLD [9]
  • Hepatomegaly secondary to biliary obstruction [9]
  • Hepatomegaly due to metastases or HCC [9]

Per lecture slides [9]:

  • May represent:
    • Hepatomegaly (biliary obstruction or metastases)
    • Distended gallbladder (Courvoisier's sign)
    • Lymph node metastases to the coeliac axis or porta hepatis
    • Distended stomach due to duodenal obstruction by tumour (gastric outlet obstruction — the same tumour can obstruct both bile duct and duodenum, e.g., CA head of pancreas)

  • Virchow's node (left supraclavicular — also called Troisier's sign): sentinel node for abdominal malignancies (lymphatic drainage via thoracic duct)
  • Sister Mary Joseph nodule: periumbilical nodule from peritoneal metastases
  • Ascites: peritoneal carcinomatosis (shifting dullness on percussion)
  • Hepatomegaly with irregular, hard, nodular edge: liver metastases
  • Trousseau syndrome (in pancreatic CA): hypercoagulable state → migratory superficial thrombophlebitis [4]
  • Paraneoplastic pemphigoid (rare, pancreatic CA) [4]

  • Positive in acute cholecystitis (not classic obstructive jaundice per se, but relevant in differential)
  • Inspiratory arrest on palpation of the RUQ — inflamed gallbladder descends with diaphragm and contacts the examining hand → pain → patient catches their breath

  • If obstruction is secondary to underlying CLD (e.g., HCC, cirrhosis): spider naevi, palmar erythema, gynaecomastia, caput medusae, splenomegaly, ascites, etc.

  • Petechiae, ecchymoses, prolonged bleeding from venepuncture sites
  • Mechanism: vitamin K deficiency → ↓factors II, VII, IX, X → coagulopathy [1]

Important History-Taking Framework

The approach to jaundice in history-taking follows a systematic exclusion [2][3]:

  • Rule out carotenaemia (eating lots of carrots/mangoes — yellow skin but NO scleral icterus) and drug-induced skin discolouration (rifampicin, quinacrine, TCMs) [3]

  • Conjugated: tea-coloured urine, pale stools, pruritus ± scratch marks
  • Unconjugated: none of the above (normal urine, normal stools, no pruritus) — think haemolysis or Gilbert's [3]

  • Medical: normal-coloured urine and stool [2]
    • Pre-hepatic (haemolysis, Gilbert's): palpitations, dizziness
    • Hepatic (hepatitis, CLD, drugs): fever, RUQ pain, N/V
  • Surgical: tea-coloured urine, pale stools, steatorrhoea [2]

As per the table above — key discriminators are age, pain, progression, and constitutional symptoms [2][3].

  • Cholangitis: Charcot's triad (fever + jaundice + RUQ pain); Reynold's pentad (add hypotension + confusion) [3]
  • CBD stone: episodic painful jaundice, history of gallstone disease, prior ERCP/surgery [3]
  • Malignant biliary obstruction: new onset, painless, progressive jaundice in old individuals; CA pancreas: constant, dull, boring epigastric pain radiating to back (usually a late feature); constitutional symptoms (LOA, LOW); metastatic symptoms [3]
  • Post-ERCP jaundice [3]

Mnemonic for hepatic causes of jaundice: "All Medical Doctors Aren't Very Happy" = Alcohol, Metabolic, Drugs, Autoimmune, Virus, HCC [2][3]


FeatureObstruction WITHOUT bacteriaObstruction WITH bacteria
ResultObstructive jaundice onlyAcute cholangitis (biliary sepsis)
Key pointBiliary bacterial contamination alone does not lead to clinical cholangitis — you need BOTH obstruction AND significant bacterial contamination [7]

This is a critical concept. Many patients with gallstones have bacteria in their bile (bactobilia) but don't develop cholangitis because bile is flowing. It's the stasis from obstruction that allows bacterial overgrowth to dangerous levels.


Pre-hepaticHepaticPost-hepatic (Obstructive)
Jaundice colourLemon yellowYellowGreenish
StoolsDark (↑stercobilin)NormalPale/clay-coloured
UrineNormalTea-colouredTea-coloured
PruritusAbsentVariablePresent ± scratch marks
LFT pattern↑Unconjugated bilirubin; normal AST/ALT, ALP, albumin↑Conjugated bilirubin; ↑↑↑AST/ALT; ↑ALP/GGT; ↓albumin if subacute↑Conjugated bilirubin; ↑AST/ALT (mild); ↑↑↑ALP/GGT; normal albumin
Key IxCBC, reticulocytes, blood film, LDH, haptoglobin, Coombs testViral serology, autoAb, liver BxUSG → MRCP/ERCP/CT

[2][3]


High Yield Summary

  1. Obstructive jaundice = conjugated hyperbilirubinaemia from impaired bile drainage → tea-coloured urine, pale stools, pruritus, steatorrhoea, vitamin K-dependent coagulopathy.

  2. Painless progressive obstructive jaundice in the elderly = malignant biliary obstruction until proven otherwise.

  3. Courvoisier's sign: painless jaundice + palpable gallbladder → unlikely stones → think periampullary tumour. Exceptions: double impaction, Mirizzi syndrome, RPC.

  4. Key differential: Stone vs Tumour — stones are episodic, painful, fluctuating in younger patients; tumours are progressive, painless, with constitutional symptoms in older patients.

  5. Pathophysiological disturbances of MBO: (a) bleeding tendency (vitamin K malabsorption + impaired clotting factor synthesis), (b) biliary sepsis (endotoxaemia, impaired RES and cell-mediated immunity), (c) poor wound/anastomotic healing (impaired protein synthesis), (d) renal impairment.

  6. LFT pattern: ↑↑↑ALP/GGT > AST/ALT (cholestatic pattern); ↑conjugated bilirubin.

  7. Most common benign cause: choledocholithiasis. Most common malignant cause: CA head of pancreas.

  8. Cholangiocarcinoma: perihilar (Klatskin) most common site; classify by Bismuth-Corlette.

  9. Biliary anatomy: RHD + LHD → CHD + cystic duct → CBD + pancreatic duct → ampulla of Vater → D2.

  10. Mnemonic for hepatic jaundice causes: "All Medical Doctors Aren't Very Happy" — Alcohol, Metabolic, Drugs, Autoimmune, Virus, HCC.


Active Recall - Obstructive Jaundice (Definition, Etiology, Clinical Features)


[1] Senior notes: felixlai.md (Malignant biliary obstruction, Acute cholangitis, Cholangiocarcinoma sections) [2] Senior notes: maxim.md (Obstructive jaundice section 5.3, Choledocholithiasis, Cholangiocarcinoma, Courvoisier's Law) [3] Senior notes: Ryan Ho GI.pdf (Section 4.1.2 Malignant Biliary Obstruction, Section B Causes of Jaundice, Section C Approach to Jaundice p191–195) [4] Senior notes: maxim.md (Pancreatic carcinoma section) [5] Senior notes: Ryan Ho GI.pdf (Section 4.8.3 Carcinoma of Pancreas p351) [6] Senior notes: Ryan Ho GI.pdf (Section 4.3.3 Cholangiocarcinoma p273) [7] Senior notes: felixlai.md (Mirizzi syndrome, RPC, Cholangiocarcinoma risk factors, Gallbladder anatomy sections) [8] Senior notes: Ryan Ho GI.pdf (Section 4.4.3 Primary Sclerosing Cholangitis p289) [9] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p3, p32)

Differential Diagnosis of Obstructive Jaundice

HCC biomarker correction: AFP is supportive, not diagnostic. Apply the validated at-risk imaging criteria or obtain histology when needed. AASLD guidance.

The differential diagnosis of obstructive jaundice is the bread and butter of hepatobiliary surgery. When a patient walks in with yellow eyes, dark urine, and pale stools, your job is threefold: (1) confirm it is truly obstructive (post-hepatic) rather than pre-hepatic or hepatocellular; (2) determine the level of obstruction; and (3) distinguish benign from malignant causes. Let's build this systematically from first principles.


Before diving into the surgical differential, you must first exclude pre-hepatic and hepatic causes. This is done clinically and biochemically [3][10][11].

Pre-hepaticHepaticPost-hepatic (Obstructive)
Jaundice colourLemon yellowYellowGreenish
StoolsDark (↑stercobilin) — more haem breakdown → more bilirubin → more stercobilinNormalPale / clay-coloured — no bilirubin reaches the gut
UrineNormal — unconjugated bilirubin is albumin-bound, not filteredTea-colouredTea-coloured — conjugated bilirubin is water-soluble, filtered by kidneys
PruritusAbsentVariablePresent ± scratch marks — bile salt deposition in skin
LFT↑Unconjugated bilirubin; AST/ALT, ALP/GGT, albumin all normal↑Conjugated bilirubin; ↑↑↑AST/ALT; ↑ALP/GGT; ↓albumin if subacute↑Conjugated bilirubin; ↑AST/ALT (mild); ↑↑↑ALP/GGT; albumin normal

Why does the LFT pattern differ?

  • In hepatocellular disease, the hepatocytes themselves are damaged → they leak their intracellular enzymes (AST, ALT) into the blood → transaminases are markedly elevated
  • In obstructive disease, the hepatocytes are largely intact but the bile ducts are blocked → ALP (alkaline phosphatase, normally present on the canalicular membrane of hepatocytes and bile duct epithelium) is induced and released into blood because of cholestasis → ALP/GGT are disproportionately elevated relative to AST/ALT [3][10]
  • GGT (gamma-glutamyl transferase) rises alongside ALP in biliary disease and confirms the ALP is of hepatobiliary origin (as opposed to bone or placental ALP) [1][10]

Types of jaundice [11]:

  • Pre-hepatic: Haemolysis (spherocytosis, G6PD deficiency, malaria, sickle cell anaemia)
  • Hepatic: hepatitis, cirrhosis, intrahepatic cholestasis, medications, Gilbert's syndrome
  • Post-hepatic: obstructive jaundice

The Classic Obstructive LFT Pattern

↑Bilirubin (conjugated), ↑↑↑ALP (± GGT) > AST/ALT (only mildly ↑) — this "cholestatic pattern" is more often seen in CA than in gallstones because malignant obstruction tends to be more complete and progressive [3][10].


Step 2: Intrahepatic vs Extrahepatic Cholestasis

Once you've established a cholestatic (obstructive) pattern, the next branch point is intrahepatic vs extrahepatic. This distinction is made primarily by ultrasound — if the intrahepatic bile ducts are dilated, the obstruction is extrahepatic (downstream block → upstream dilatation). If the ducts are not dilated, the problem is intrahepatic (at the level of hepatocytes or small ductules) [10][14].

These are "medical" causes — the bile ducts are structurally patent, but bile formation or small-duct flow is impaired:

CauseMechanism
Hepatocyte dysfunction (hepatitis of any cause, end-stage liver disease)Damaged hepatocytes → ↓excretion of conjugated bilirubin into canaliculi [3]
Drugs (anabolic steroids, OCP, chlorpromazine, arsenic)Drug-induced cholestasis — interference with bile salt transport proteins on canalicular membrane
Primary biliary cholangitis (PBC)Autoimmune destruction of small intrahepatic ducts → progressive cholestasis; characterised by +ve AMA (anti-mitochondrial antibody), middle-aged women [15]
Primary sclerosing cholangitis (PSC) — small duct variantInflammation and fibrosis of small ducts; may have normal cholangiography
No enteric intake (TPN, post-operative)↓CCK secretion → ↓gallbladder contraction → bile stasis [3]
Intrahepatic cholestasis of pregnancyAssociated with ↑oestrogen levels → impaired bile salt transport [3]
Intrahepatic compression of bilateral bile ducts by massive liver SOLVery uncommon — requires bilateral duct compression (e.g., massive HCC) [3]
Congenital (Dubin-Johnson syndrome, Rotor syndrome)Defective canalicular transport of conjugated bilirubin [10]

For intrahepatic cholestasis workup: clinical Hx for drugs, TPN use and infiltrative diseases → AMA and Ig pattern for PBC → viral hepatitis serology → liver biopsy if persistently > 2× ULN for > 6 months without identifiable cause [14]

This is the true "surgical" obstructive jaundice and forms the core of our differential. Organised by relationship to the duct wall [1][2][3]:


This is the framework you must know cold for exams:


Detailed Differential Diagnosis by Category

CauseKey FeaturesWhy It Causes Obstruction
CBD stones (choledocholithiasis)Most common cause of obstructive jaundice overall. Episodic, painful jaundice in younger individuals with Hx of gallstone disease [2][3]. Fluctuating jaundice (ball-valve effect).Stone migrates from GB via cystic duct → impacts at distal CBD/ampulla → mechanical blockage of bile flow
Cholangitis / RPCCharcot's triad (fever + jaundice + RUQ pain); Reynold's pentad adds hypotension + confusion [1][13]. RPC: recurrent episodes, a/w liver flukes in HK/southern ChinaIntraluminal stones + pus + debris block bile flow; in RPC, primary intrahepatic pigment stones cause recurrent obstruction and infection
Parasites (Ascaris lumbricoides, liver flukes — Clonorchis sinensis, Opisthorchis viverrini)Travel Hx, endemic area (SE Asia), may see worms on ERCPAdult worms or ova physically obstruct the bile duct lumen; chronic infection → inflammation → stone formation (pigment stones)
Tumour thrombus (rare, in HCC)Known CLD/HCC. Very uncommon cause of MBOHCC extends as a tumour thrombus into the bile duct lumen (analogous to portal vein tumour thrombus)
Haemobilia (very rare)Post-trauma, post-ERCP, hepatic artery aneurysm. Presents with Quincke's triad: jaundice + biliary colic + GI bleedingBlood clot within the bile duct lumen obstructs flow

CauseKey FeaturesWhy It Causes Obstruction
Benign stricturesHistory of prior ERCP/surgery, chronic pancreatitis, or repeated stone passage → fibrotic narrowing of duct wallPost-inflammatory fibrosis or surgical injury → circumferential narrowing of the duct from within the wall
Primary sclerosing cholangitis (PSC)Young men (70% male, 25–40 y); strongly associated with UC [8]. Characteristic "beaded" cholangiogram. Intermittent jaundice, pruritus, fatigueChronic autoimmune inflammation → fibrosis and stricturing of medium and large intra-/extrahepatic ducts → progressive narrowing
Sphincter of Oddi dysfunctionIntermittent symptoms (episodic pain and transient LFT derangement); post-cholecystectomyFunctional spasm or fibrosis of the sphincter of Oddi → intermittent obstruction of bile (and sometimes pancreatic juice) flow
Cholangiocarcinoma (mural)Painless obstructive jaundice; perihilar (Klatskin) tumours ~50%, distal ~40%. Hilar/distal tumours tend to present earlier because they obstruct bile flow at a critical point [6][7]. Slow-growing, locally invasive.Malignant proliferation of bile duct epithelium → intrinsic narrowing of the duct lumen. Marked desmoplastic reaction contributes to progressive stenosis

Intrahepatic Cholangiocarcinoma Does NOT Cause Jaundice Early

Intrahepatic cholangiocarcinoma will NOT cause jaundice in early stages because bilirubin can be reabsorbed into blood and re-excreted through unaffected parts of the liver. Only extrahepatic (perihilar/distal) cholangiocarcinoma causes jaundice, especially Klatskin tumour where blockage of the bifurcation of L and R hepatic ducts causes jaundice in early stage [7].

CauseKey FeaturesWhy It Causes Obstruction
CA head of pancreasMost common malignant cause of obstructive jaundice. Painless progressive obstructive jaundice (tumour at head) [4]. 60% arise in head. Double duct sign on CT [5][12]. Courvoisier's sign +ve. Constitutional symptoms. New-onset DM, steatorrhoea. Trousseau syndromeTumour in pancreatic head extrinsically compresses/encases the intrapancreatic segment of the CBD from outside
CA ampulla of VaterClassically a/w silvery stools (Thomas's sign) — combination of clay (obstructed) and tarry (bleeding from friable ampullary tumour) stools [3][10]. May cause intermittent jaundice (tumour may ulcerate and slough → transient relief)Tumour at the ampulla obstructs the distal-most CBD/pancreatic duct from outside/at the junction
CA duodenum (periampullary)Rare. May cause GOO in addition to obstructive jaundiceDuodenal tumour in the periampullary region compresses or invades the distal CBD
Mirizzi syndromePainful jaundice (unlike typical MBO); Hx of gallstone disease. Large stone impacted in cystic duct/Hartmann's pouchExtrinsic compression of CHD by impacted gallstone + secondary inflammation. Chronic cases may fistulise into CHD [1][7]
Pancreatitis (acute/chronic)Acute: epigastric pain radiating to back, ↑amylase/lipase. Chronic: calcifications, steatorrhoeaInflammatory oedema (acute) or fibrosis (chronic) of the pancreatic head → extrinsic compression of intrapancreatic CBD
Porta hepatis lymphadenopathyKnown primary malignancy (CA stomach, CA gallbladder, HCC, lymphoma) [3]. Systemic SxEnlarged metastatic lymph nodes at the porta hepatis compress the CHD/CBD from outside
Choledochal cystsUsually diagnosed in childhood ( < 10 y in 60%). RUQ mass + pain, jaundice, fever. Risk of cholangiocarcinoma [7]Congenital cystic dilatation of bile duct → stasis, inflammation, or compression of adjacent normal duct

This is a high-yield exam framework — what's dilated on imaging tells you where the block is, and the differential changes accordingly [1]:

LevelWhat Is DilatedDifferential Diagnosis
Hilum (confluence of R + L hepatic ducts)Intrahepatic ducts bilaterally; CHD/CBD may be normal calibreKlatskin tumour (perihilar cholangiocarcinoma), CA gallbladder, HCC, Mirizzi syndrome, porta hepatis lymphadenopathy, PSC, RPC [1]
Mid-CBDIntrahepatic ducts + CHD dilated; CBD dilated above the level of the blockCholangiocarcinoma of CBD, CA head of pancreas, lymphadenopathy [1]
Distal CBDEntire biliary tree dilated (intrahepatic + CHD + CBD)CBD stones, benign bile duct strictures, periampullary carcinoma (ampulla/duodenum), choledochal cysts, pancreatic cysts, chronic pancreatitis [1]

Exam Tip — Double Duct Sign

Double duct sign = simultaneous dilatation of both the CBD and the pancreatic duct on imaging. This occurs when a mass at their common termination point (head of pancreas or ampulla) obstructs both ducts. It is virtually pathognomonic of CA ampulla or CA head of pancreas [5][12].


This is the clinical crux of the differential and comes up repeatedly in exams and on ward rounds [2][3]:

FeatureStone (Benign)Tumour (Malignant)
AgeYoungerOlder (> 60 y)
OnsetSudden, episodicGradual, progressive
PainPainful (biliary colic, RUQ pain)Painless (classic); dull boring epigastric pain radiating to back only in CA body/tail of pancreas (late)
FeverCommon (cholangitis)Uncommon initially
JaundiceFluctuating (ball-valve)Progressive, deepening
Constitutional SxMinimalLOA, LOW, malaise
GallbladderNot palpable (fibrosed from chronic cholecystitis)Palpable, non-tender (Courvoisier's sign)
LFTCholestatic, may fluctuateCholestatic pattern more pronounced and sustained
HistoryPrior biliary colic, known gallstones, ERCPNo prior biliary Hx; new-onset DM may be a clue for CA pancreas

Steatorrhoea (floating, foul-smelling, difficult to flush) can occur in both but is more prominent in malignant obstruction (complete and prolonged) and especially in CA pancreas (which also obstructs the pancreatic duct → exocrine insufficiency) [2].


Step 6: Special Differentials Worth Knowing

When a patient develops jaundice after surgery, the differential shifts:

  • Pre-hepatic: haemolysis (e.g., blood transfusion reaction)
  • Hepatic: halogenated anaesthetics (hepatotoxicity), sepsis, intra-/post-operative hypotension → ischaemic hepatitis
  • Post-hepatic: biliary injury (surgical damage to bile duct during cholecystectomy — most feared complication)

Per Prof R Poon's lecture [9]:

  • Hepatomegaly (mild) due to biliary obstruction
  • Hepatomegaly due to metastasis or HCC
  • LN metastasis to coeliac axis and porta hepatis
  • CA stomach with metastatic LN in porta hepatis
  • Tumour obstructing both duodenum and bile duct → distended stomach + jaundice

When cholangiocarcinoma is suspected, the differential includes:

  • Choledocholithiasis
  • Viral hepatitis
  • Hepatocellular carcinoma (AFP helps distinguish — AFP >400 is concerning but cannot diagnose HCC without appropriate imaging or histology [3])
  • Other malignant biliary obstruction: pancreatic cancer, CA ampulla of Vater
  • Intrahepatic cholestasis: PSC, PBC
  • IgG4-related sclerosing cholangitis — important mimic of cholangiocarcinoma; check serum IgG4 [7]

IgG4-Related Sclerosing Cholangitis — The Great Mimic

IgG4-related sclerosing cholangitis can mimic cholangiocarcinoma both clinically and radiologically (stricturing of bile ducts, mass lesion). Always check serum IgG4 levels. This is a treatable condition (responds to corticosteroids) — you do NOT want to do a Whipple's for autoimmune disease!


CategorySubcategoryCauseDistinguishing Features
IntrahepaticHepatocyte dysfunctionHepatitis (viral, alcoholic, drug-induced, autoimmune), end-stage liver disease↑↑↑AST/ALT, ± fever, Hx of exposure/drugs/alcohol
DrugsAnabolic steroids, OCP, chlorpromazine, arsenicTemporal relationship with drug use
AutoimmunePBCMiddle-aged female, +ve AMA, pruritus, xanthomata [15]
PSC (small duct)Young male, a/w UC, normal cholangiogram, need Bx
PregnancyIntrahepatic cholestasis of pregnancy3rd trimester, pruritus, resolves post-delivery
Functional stasisTPN, post-operativeNo enteric intake → ↓CCK → ↓GB contraction
CompressionMassive liver SOLVery uncommon
CongenitalDubin-Johnson, Rotor syndromeConjugated hyperbilirubinaemia, benign, no treatment needed
Extrahepatic — IntraluminalStonesCBD stonesEpisodic, painful, fluctuating jaundice, younger
InfectionCholangitis, RPCCharcot's triad; RPC in endemic areas
ParasitesAscaris, Clonorchis, OpisthorchisTravel Hx, endemic area
TumourTumour thrombus (HCC)Known HCC/CLD
BloodHaemobiliaPost-trauma/procedure, Quincke's triad
Extrahepatic — MuralBenignBenign stricturesPost-ERCP, post-surgery, chronic pancreatitis
PSC (large duct)Young male, UC, "beaded" cholangiogram
Sphincter of Oddi dysfunctionIntermittent, post-cholecystectomy
MalignantCholangiocarcinomaPainless jaundice; perihilar (Klatskin) most common site
Extrahepatic — ExtramuralMalignantCA head of pancreasPainless progressive jaundice, Courvoisier's +, double duct sign, new-onset DM
CA ampulla of VaterSilvery stools (Thomas's sign), intermittent jaundice
CA duodenumRare, may cause GOO
Porta hepatis LNKnown primary malignancy
BenignMirizzi syndromePainful jaundice, Hx gallstones, extrinsic CHD compression
Acute/chronic pancreatitisPain, ↑amylase; chronic: calcifications
Choledochal cystsYoung, congenital, RUQ mass

The following mermaid diagram synthesises the clinical approach to narrowing the differential when you see a jaundiced patient [2][3][10][14]:

Key principle: The USG is the gatekeeper. Dilated intrahepatic ducts → extrahepatic cholestasis (surgical). No dilatation → intrahepatic cholestasis (medical) [10][14]. This single finding dictates the entire downstream workup.


Take tumour markers with extreme caution in MBO! [3][10]

MarkerUsePitfall
CA 19-9CA pancreas, cholangiocarcinoma (raised in ~80%)CA 19-9 is excreted via bile → invariably ↑ in ANY cholestasis. Always take CA 19-9 after relief of obstruction for accurate interpretation. Also requires Lewis blood group antigen to be expressed (5–10% of population are Lewis-negative → CA 19-9 will always be low) [3][10][1]
CEAAdenocarcinoma (raised in 30–60% of CA pancreas)Highly non-specific — elevated in many GI conditions. Probably has little role in initial diagnosis. Take it pre-operatively as baseline for post-operative monitoring [3][10]
AFPHCC (> 400 is diagnostic)Rarely useful as HCC is rarely the cause of MBO [3][10]. But important if intrahepatic cholangiocarcinoma is being differentiated from HCC (AFP is usually normal in cholangiocarcinoma)

CA 19-9 and Cholestasis — A Common Exam Trap

Students frequently make the mistake of interpreting an elevated CA 19-9 in a jaundiced patient as evidence of malignancy. CA 19-9 is excreted in bile. ANY biliary obstruction will raise CA 19-9 regardless of the cause. You MUST relieve the obstruction first, then recheck CA 19-9 for a meaningful result [3][10].


We covered this in Part 1 but it bears repeating here as it's a critical differential tool:

"In painless jaundice, if the gallbladder is palpable, it is unlikely to be due to gallstones" → points to malignant biliary obstruction (periampullary tumour) [1][3][10]

Exceptions [3][10]:

  1. Double stone (CBD + cystic duct)
  2. Recurrent pyogenic cholangitis
  3. In situ CBD stones (in RPC)
  4. Mirizzi syndrome (rare)
  5. Pancreatic stone (rare)

High Yield Summary — Differential Diagnosis

  1. Framework: First exclude pre-hepatic/hepatic causes → Confirm extrahepatic cholestasis by USG (dilated ducts) → Classify as intraluminal/mural/extramural → Differentiate stone vs tumour.

  2. Intraluminal: CBD stones (most common), cholangitis/RPC, parasites, tumour thrombus, haemobilia.

  3. Mural: benign strictures, PSC, sphincter of Oddi dysfunction, cholangiocarcinoma.

  4. Extramural: CA head of pancreas (most common malignant cause), CA ampulla/duodenum, Mirizzi syndrome, pancreatitis, porta hepatis LN, choledochal cysts.

  5. Level of obstruction guides the DDx: hilum → Klatskin, HCC, Mirizzi, PSC, RPC; mid-CBD → cholangiocarcinoma, CA pancreas, LN; distal CBD → stones, strictures, periampullary CA.

  6. CA 19-9 is unreliable in cholestasis — always interpret after biliary drainage.

  7. Thomas's sign (silvery stools) = CA ampulla; Double duct sign = CA head of pancreas or CA ampulla.

  8. IgG4-related sclerosing cholangitis is a treatable mimic of cholangiocarcinoma — always check IgG4.

  9. Intrahepatic cholangiocarcinoma does NOT cause early jaundice — only extrahepatic (perihilar/distal) does.


Active Recall - Differential Diagnosis of Obstructive Jaundice


References

[1] Senior notes: felixlai.md (Malignant biliary obstruction — causes by level of obstruction, Cholangiocarcinoma risk factors, Mirizzi syndrome) [2] Senior notes: maxim.md (Obstructive jaundice section 5.3, Choledocholithiasis, Post-operative jaundice DDx) [3] Senior notes: Ryan Ho GI.pdf (Section 4.1.2 Malignant Biliary Obstruction p194, Causes of Jaundice p191, Approach to Jaundice p192) [4] Senior notes: maxim.md (Pancreatic carcinoma section) [5] Senior notes: Ryan Ho GI.pdf (Section 4.8.3 Carcinoma of Pancreas p351) [6] Senior notes: Ryan Ho GI.pdf (Section 4.3.3 Cholangiocarcinoma p273) [7] Senior notes: felixlai.md (Cholangiocarcinoma clinical manifestation and differential diagnosis) [8] Senior notes: Ryan Ho GI.pdf (Section 4.4.3 Primary Sclerosing Cholangitis p289) [9] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p32) [10] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.3.10 Malignant Biliary Obstruction p297–299, Courvoisier's law, tumour markers caution box) [11] Lecture slides: Malignant biliary obstruction.pdf (p2 — Types of jaundice) [12] Senior notes: Ryan Ho Fundamentals.pdf (CT abdomen pancreas protocol findings p299) [13] Senior notes: Ryan Ho Fundamentals.pdf (RUQ Pain differential p307, Physical examination and D/dx of epigastric mass + jaundice p296) [14] Senior notes: Ryan Ho Fundamentals.pdf (Evaluation of ↑ALP p307) [15] Senior notes: Ryan Ho GI.pdf (Section on PBC diagnostic criteria p286)

Diagnostic Criteria for Obstructive Jaundice

HCC biomarker correction: AFP is supportive, not diagnostic. Apply the validated at-risk imaging criteria or obtain histology when needed. AASLD guidance.

There is no single "diagnostic criteria set" for obstructive jaundice the way there is for, say, rheumatoid arthritis. Instead, the diagnosis is established through a convergence of clinical, biochemical, and imaging findings. However, specific diagnostic criteria exist for acute cholangitis (the most dangerous complication of biliary obstruction), and there are well-defined biochemical and imaging patterns that confirm the diagnosis.

The diagnosis of obstructive jaundice rests on recognising the cholestatic (ductal) LFT pattern [3][10][13]:

ParameterExpected FindingWhy
Conjugated bilirubin↑↑Conjugated bilirubin cannot be excreted → regurgitates into blood
ALP↑↑↑ALP is an enzyme located on the canalicular membrane of hepatocytes and bile duct epithelium. Cholestasis induces ALP synthesis and forces it into the blood
GGT↑↑↑Rises alongside ALP in biliary disease; confirms hepatobiliary origin of elevated ALP (ruling out bone or placental sources) [1][7]
AST / ALTMildly ↑Hepatocytes are not primarily damaged; mild elevation reflects secondary cholestatic injury. The classic obstructive picture is ALP/GGT >> AST/ALT
AlbuminUsually normalHepatic synthetic function is preserved in early-to-moderate obstruction (unlike hepatocellular disease where albumin drops)

The classical obstructive pattern (↑bilirubin, ↑↑↑ALP/GGT >> mildly ↑AST/ALT) is more often seen in malignancy than in gallstones [3][10] — because malignant obstruction tends to be more complete and sustained.

A key distinction: ↑INR may be due to hepatocellular dysfunction (unresponsive to vitamin K) or cholestasis (responsive to IV vitamin K) [13]. This is a critical clinical test — if you give parenteral vitamin K and the INR corrects within 24–48 hours, the coagulopathy is from malabsorption (obstructive). If it doesn't correct, the liver parenchyma is failing.

The imaging hallmark of extrahepatic obstruction is dilatation of the biliary tree proximal to the obstruction [3][10]:

ParameterNormalPathological
Intrahepatic ductsNot visible on USG ( < 2–3 mm)Visible, dilated (the "parallel channel" or "shotgun" sign — dilated duct running alongside a portal vein branch) [1]
CBD diameter≤6–8 mm> 8 mm is pathological (some use > 6 mm); post-cholecystectomy can be up to 10–11 mm [1][2][10]

When obstruction is complicated by infection, the diagnosis shifts to acute cholangitis. The Tokyo Guidelines provide formal criteria [1]:

Suspected diagnosis — requires BOTH of:

  1. ONE of the following: fever or shaking chills OR laboratory evidence of inflammation (abnormal WBC, ↑CRP)
  2. ONE of the following: jaundice OR abnormal liver chemistries (↑AST/ALT/ALP/GGT)

Definite diagnosis — in addition to meeting suspected criteria, requires BOTH of:

  1. Biliary dilatation on imaging
  2. Evidence of aetiology on imaging (e.g., stone, stricture, stent)

Severity grading:

  • Grade I (mild): does not meet criteria for Grade II or III
  • Grade II (moderate): any two of — WBC > 12,000 or < 4,000; fever ≥ 39°C; age ≥ 75 y; bilirubin ≥ 85 µmol/L; albumin < 0.7× LLN
  • Grade III (severe): organ dysfunction — cardiovascular (hypotension requiring vasopressors), neurological (altered consciousness), respiratory, renal, hepatic, or haematological (DIC)

Clinical Pearl — Reynold's Pentad

Reynold's pentad (present in < 10% of cholangitis patients) adds hypotension + altered mental status (confusion) to Charcot's triad (fever + jaundice + RUQ pain). This indicates suppurative cholangitis — a surgical emergency with septic shock progressing to multiorgan failure [1].


Diagnostic Algorithm

The approach is systematic and sequential. Think of it as four progressive goals [3][10]:

Goals of imaging [3][10]:

  1. Extrahepatic vs intrahepatic cholestasis
  2. Level of obstruction
  3. Identify exact cause
  4. Staging of cancer (if malignant)

Before we draw the flowchart, let's understand the logic behind it [3][10]:

  • Management of biliary sepsis is the FIRST priority → it can quickly kill! [3][10]
  • Drainage is NOT ALWAYS URGENT — the effect on liver function is slow in onset → drainage should ideally be done after CT abdomen if there are no indications for early decompression, to allow better tumour assessment [3][10]
  • Endoscopic stenting will affect evaluation of the tumour on subsequent imaging → do CT before ERCP whenever possible [12]
  • Indications for early drainage [3][10]:
    • Biliary sepsis or stones (stone formation usually indicates a contaminated biliary system)
    • Poor liver function due to prolonged cholestasis → must be optimised pre-operatively
    • Klatskin tumour — drainage allows normalisation of liver function, which is important for pre-operative ICG testing and post-operative monitoring (as hepatectomy is part of management)
  • Drainage procedures carry significant risks → always balance risk vs benefit [3][10]
  • In HK, delayed drainage is often not realistic as patients need to wait months for OT [3]


Investigation Modalities — Detailed

1. Blood Tests (Bedside / Laboratory)

These are your first investigations — ordered from the Emergency Department before any imaging [1][3][10]:

TestFinding in ObstructionInterpretation
Bilirubin (total and direct)↑ Conjugated (direct) bilirubinConfirms post-hepatic cause; ↑bilirubin indicates complete obstruction; normal bilirubin may indicate SOL pressing on hepatic sinusoids without complete duct obstruction [14]
ALP↑↑↑Canalicular enzyme induced by cholestasis. Must confirm hepatic origin with GGT and heat-stability index (HSI) [14]
GGT↑↑↑Elevation of GGT confirms the excess ALP is of hepatobiliary origin [1][7]
AST/ALTMildly ↑Secondary hepatocyte stress from cholestasis; transaminase levels may initially be normal but elevate when chronic biliary obstruction leads to liver dysfunction [7]
AlbuminNormal (early); ↓ (late/chronic)Assesses nutritional status and hepatic synthetic reserve
PT/INR↑Vitamin K malabsorption → ↓factors II, VII, IX, X. Key test: give IV vitamin K → if INR corrects = cholestasis; if not = hepatocellular dysfunction [13]

FindingSignificance
LeukocytosisAssociated biliary sepsis (neutrophil predominance in cholangitis) [1]
AnaemiaChronic disease, GI blood loss (ampullary tumour), malignancy
ThrombocytopeniaImportant to check when planning for invasive procedures such as ERCP [1]; may indicate hypersplenism if underlying cirrhosis
PancytopeniaUnderlying cirrhosis with hypersplenism [1]

  • Check RFT for suitability of contrast CT [3][10] — IV contrast is nephrotoxic; need adequate renal function (eGFR)
  • Also monitors for hepatorenal syndrome in prolonged obstruction

  • Rule out concomitant biliary pancreatitis [3][10] — a CBD stone impacted at the ampulla can obstruct both the bile duct and the pancreatic duct simultaneously

  • Coagulopathy due to vitamin K malabsorption, DIC, or liver disease [3][10]
  • Must be corrected before any invasive procedure

  • For biliary sepsis — should be taken before starting antibiotics [3][10]
  • Common organisms: E. coli, Klebsiella pneumoniae, Enterococcus sp., Enterobacter sp., Bacteroides fragilis [1]

Tumour Markers — Handle with Extreme Caution in MBO!

Take tumour markers with extreme caution in MBO! [3][10]:

  • CA 19-9 is excreted via bile → invariably ↑ in ANY cholestasis. Always take CA 19-9 AFTER relief of obstruction for accurate interpretation. Also requires Lewis blood group antigen to be expressed (5–10% of population are Lewis-negative → CA 19-9 always low) [3][10]
  • CEA is highly non-specific and probably has little role in initial diagnosis. Take it pre-operatively as a baseline [3][10]
  • AFP is rarely useful as HCC is rarely the cause of MBO [3][10]. However, AFP >400 is concerning but cannot diagnose HCC without appropriate imaging or histology and helps differentiate intrahepatic cholangiocarcinoma from HCC [7]
  • Tumour markers are NOT sensitive and NOT specific for periampullary tumours — absence of elevated markers does NOT exclude malignancy [1]
MarkerRelevancePitfall
CA 19-9CA pancreas (raised in ~80%), cholangiocarcinomaInvariably ↑ in cholestasis; also ↑ in chronic pancreatitis, cholangitis, gastric CA, HCC. Useful for serial monitoring after resection for recurrence [1][7]
CEAAdenocarcinoma (raised in 30–60%)Non-specific; also ↑ in gastritis, PUD, diverticulitis, CRC, lung/breast CA [7]
AFPHCC ( > 400 diagnostic)Normal in cholangiocarcinoma (helps differentiate from HCC); rare combined HCC-cholangioCA may have high AFP [7]

TestIndication
HBV and HCV serologyScreen for underlying chronic liver disease / HCC [1]
Serum IgG4Evaluate for IgG4-related sclerosing cholangitis — a treatable mimic of cholangiocarcinoma [7]
Serum glucoseAssess for presence of DM — DM is both a risk factor for and a consequence of pancreatic CA; new-onset DM in an older adult should prompt screening for pancreatic CA [1]
Inflammatory markers (ESR, CRP)Support diagnosis of cholangitis / infection [1]
UrinalysisBile (conjugated bilirubin) present in urine in obstructive jaundice; absent urobilinogen in complete obstruction [1]

2. Imaging — The Core of Diagnosis

Imaging modalities for obstructive jaundice (per Prof R Poon's lecture) [16]:

  • Ultrasonography
  • Endoscopic ultrasonography
  • Endoscopic retrograde cholangiopancreatography (ERCP)
  • Percutaneous transhepatic cholangiography (PTC) and drainage (PTBD)
  • Computed tomography (CT)
  • Magnetic resonance imaging (MRI) and cholangiopancreatography (MRCP)
  • Positron emission tomography (PET)

Why first? It is non-invasive, inexpensive, widely available, no radiation, no contrast, and answers the single most important question: are the bile ducts dilated? [3][10]

Main aim: look for any dilated biliary system → indicates extrahepatic cholestasis [3][10]

FindingSignificance
Dilated intrahepatic ducts (> 2–3 mm, visible on USG)Confirms extrahepatic obstruction
Dilated CBD ( > 6–8 mm)Confirms extrahepatic obstruction; CBD > 8 mm is pathological [1][2]
CBD stoneVisible in only ~1/3 of cases due to obscuring gas in duodenum [2]
GB stone/sludgeSource of potential choledocholithiasis
Thickened GB wall, pericholecystic oedema, strandingSuggests cholecystitis [10]
Thickened CBD wallSuggests cholangitis [10]
Enlarged LNs, liver secondaries, ascitesFeatures of malignancy / metastatic disease [10]
Palpable GB correlate (distended GB on USG)Supports Courvoisier's sign

Disadvantages: usually unable to visualise the primary tumour and distal biliary system — the CBD, ampulla, and pancreas are obscured behind the second part of the duodenum (D2) by bowel gas [2][3][10]. This is why USG alone is insufficient for malignant causes.

USG Limitation — The Distal CBD Blind Spot

The most common site of pathology (distal CBD stone, CA head of pancreas, CA ampulla) is the hardest to see on USG because the retroperitoneal pancreas and gas-filled duodenum block the ultrasound beam. A normal USG does NOT rule out distal obstruction — if clinical suspicion is high, proceed to CT or MRCP regardless.

This is your workhorse investigation when malignancy is suspected. It serves a dual purpose: diagnosis and staging [3][10][12].

Timing/Role: Can be the initial investigation if suspicious for MBO [3][10][12]:

  • Before USG — because a positive USG will need CT for diagnosis/staging anyway
  • Before ERCP — because endoscopic stenting will affect evaluation of the tumour [12]

Pancreatic protocol: thin-sliced triphasic CT specifically designed to visualise pancreatic lesions [12]:

  • Oral water contrast to improve image quality + ↓artefacts
  • Early arterial phase (~25 seconds) → visualises aorta/SMA invasion; if mass is enhancing, more likely neuroendocrine tumour [12]
  • Pancreatic phase (~40 seconds) → visualises parenchymal lesions (the pancreas enhances maximally; a hypoenhancing mass stands out) [12]
  • Delayed (portovenous) phase (~70 seconds) → visualises liver secondaries (metastases are typically hypovascular against the brightly enhancing liver parenchyma) [12]

Accuracy: ~90% overall (67% if tumour ≤ 3 cm), but only 70% accurate for predicting unresectability [3][12]

Key CT Findings:

FindingInterpretation
Double duct signSimultaneous dilatation of pancreatic duct + CBD → indicates CA ampulla or CA head of pancreas [12]
Ductal dilatation ( > 6 mm) without stonesLikely malignant stricture [12]
Hypoenhancing pancreatic massCA pancreas — the tumour is hypovascular (poor blood supply) relative to normal pancreatic parenchyma [12]
Hypovascular liver massLiver secondaries (metastases) [12]
Ascites, peritoneal nodulesFeatures of metastatic disease [12]
Vascular encasement / abutmentAssesses resectability: involvement of SMA, hepatic artery, coeliac trunk, SMV, portal vein [4]

"MRCP" = Magnetic Resonance CholangioPancreatography — an MRI sequence that uses heavily T2-weighted images to make fluid-filled structures (bile ducts, pancreatic duct) appear bright white, producing a non-invasive cholangiogram without contrast injection or endoscopy [1][3][10].

Role: MRCP is used when intervention is not required — i.e., when you want to visualise the biliary anatomy without the risks of ERCP [3][10]. MRCP has largely replaced ERCP as a diagnostic tool [1].

Indications:

  • Patients without high suspicion of biliary obstruction — e.g., mild elevation of bilirubin and ALP with equivocal CT findings [1]
  • When endoscopic bile duct decompression is not likely to be necessary [2]
  • Delineate biliary anatomy before surgery (e.g., for Klatskin tumour — defines extent of disease and remaining functional liver)
  • If ERCP is contraindicated (e.g., altered anatomy post-gastrectomy)

Advantages over ERCP:

  • Non-invasive (no sedation, no endoscopy, no radiation)
  • No risk of post-ERCP pancreatitis
  • Excellent for delineating the biliary tree anatomy, level and cause of obstruction

Disadvantages:

  • Cannot be therapeutic — cannot place stents, remove stones, or take biopsies
  • Contraindicated if patient has MRI-incompatible metallic implants
  • Motion artefact in uncooperative patients

"ERCP" = Endoscopic (through an endoscope) Retrograde (injecting contrast backwards up the bile duct) Cholangio (bile duct) Pancreatography (imaging of the pancreatic duct).

This is the gold standard for direct cholangiography and has the unique advantage of being both diagnostic and therapeutic [3][10][12].

Diagnostic Indications [12]:

  • Obstructive jaundice for workup
  • Suspected CBD stone
  • Suspected biliary pancreatitis
  • Suspected periductal malignancies (extrahepatic cholangioCA, CA head of pancreas, CA ampulla)
  • Suspected sphincter of Oddi dysfunction
  • Suspected biliary strictures and RPC

Therapeutic Capabilities [12]:

  • Endoscopic sphincterotomy (cutting the sphincter of Oddi to widen the opening)
  • Stent insertion and removal (over guidewire — plastic or metallic self-expanding stents)
  • Dilatation of strictures (by balloon)
  • Retrieval of stones (by basket or balloon)
  • Brush biopsy (sensitivity ~60% only — a limitation) [12]
  • Snare ampullary resection in CA ampulla (not curative) [12]

When to choose ERCP over MRCP? When endoscopic bile duct decompression is likely to be necessary — i.e., high suspicion of stone, biliary sepsis requiring drainage, or need for stenting [2][3][10].

Complications of ERCP (significant — this is why you don't do ERCP purely for diagnosis if MRCP can answer the question):

  • Post-ERCP pancreatitis (most common significant complication, ~3–5%)
  • Perforation (duodenal or bile duct)
  • Bleeding (post-sphincterotomy)
  • Cholangitis/sepsis (if incomplete drainage)
  • Bacteraemia (thus antibiotic prophylaxis is required) [2]

ERCP — Not Just Diagnostic Any More

In modern practice, MRCP has largely replaced ERCP as a purely diagnostic tool [1]. ERCP is now reserved primarily for therapeutic intervention or when high clinical suspicion warrants simultaneous diagnosis and treatment (e.g., CBD stone with cholangitis). Don't subject a patient to ERCP risks just for diagnosis when MRCP can give you the same information non-invasively.

"PTC" = injecting contrast through the skin and liver into a bile duct; "PTBD" = leaving a drainage catheter in place.

Aim: relieves biliary obstruction [17]

Technique: Involves puncturing of a duct through skin and liver → contrast injected into biliary tree → ducts opacified during fluoroscopy → provides imaging guidance for drainage [17]

Requires antibiotic coverage [17]

Indications [17]:

  • Treat obstructive jaundice (benign or malignant) — e.g., cholangiocarcinoma
  • Treat biliary sepsis (cholangitis)
  • Treat post-operative bile leaks (due to surgical damage to biliary tree)
  • Pre-operative decompression of biliary system — improve drainage → better liver function to facilitate post-surgical recovery (controversial) [17]

When PTC/PTBD over ERCP?

  • ERCP failure or contraindication (e.g., altered anatomy post-gastrectomy, Roux-en-Y, complete duodenal obstruction)
  • Proximal (hilar) tumours — ERCP is preferred for distal tumours; PTC is preferred for proximal tumours [6] because the endoscope approaches from below and may not adequately opacify ducts above a complete hilar block
  • When percutaneous access is needed for bilateral drainage in Bismuth III/IV tumours

May involve use of [17]:

  • Plastic/metallic stents
  • Balloon dilatation

Acute complications (5–10%) [17]:

  • Bleeding into biliary system (most common)
  • Infection: septic shock
  • Pancreatitis (due to CBD damage — rare)
  • Puncturing other organs (e.g., lungs, kidneys)

Delayed complications (45–50%) [17]:

  • Biliary sepsis (cholangitis)
  • Catheter migration
  • Bile leak (→ irritation)
  • Metastatic seeding
  • Skin infection

Contraindication: biliary sepsis is listed as a contraindication for elective cholangiography [18], though emergent PTBD for cholangitis is performed when ERCP has failed — the distinction is that you should not inject contrast for diagnostic purposes into an infected biliary system without providing drainage.

EUS combines endoscopy with a high-frequency ultrasound probe at the tip. Because the transducer sits right next to the pancreas and bile duct (through the duodenal/gastric wall), it gives exquisite detail of these structures without the interference of bowel gas [1][3][10].

Roles [1][3][10]:

  • Diagnosis: visualise pancreatic masses, bile duct wall thickening, LN involvement
  • Staging: nodal involvement [6], T-staging of periampullary tumours
  • Tissue diagnosis: EUS-guided FNAC/biopsy — preferred over percutaneous USG/CT-guided biopsy for pancreatic masses (↓risk of tumour seeding along the percutaneous tract) [4]

Specific roles:

  • CA head of pancreas: normally cannot be seen with OGD unless it has invaded through the wall of duodenum → EUS helps acquire histological diagnosis before attempting Whipple operation [1]
  • Cholangiocarcinoma: EUS with brush cytology can be performed but with low sensitivity and specificity; EUS cannot reach the lumen of bile duct in the majority of cases → may require mother-baby cholangioscopy (SpyGlass) for direct visualisation and biopsy [1]
  • NO role in diagnosing CA ampulla of Vater and CA duodenum — these are visible on standard OGD and can be biopsied directly [1]

Positron emission tomography uses FDG (fluorodeoxyglucose) to detect metabolically active tumour deposits [16].

Role: primarily for staging — detecting distant metastases not seen on CT, assessing equivocal lesions, and evaluating treatment response. May change management in up to 15–20% of cases by detecting occult metastases.

Not used for initial diagnosis.

A minimally invasive surgical procedure to directly inspect the peritoneal cavity.

Role: detect occult peritoneal/liver metastases not visible on cross-sectional imaging. Particularly important before committing to a major resection (e.g., Whipple's procedure or hepatectomy for Klatskin tumour) [6].

Role: direct visualisation of the bile duct lumen via a miniature endoscope passed through the working channel of a duodenoscope (during ERCP). Allows targeted biopsy of intraductal lesions. Used when ERCP brush cytology is non-diagnostic and tissue diagnosis is critical [1].


This is a nuanced topic. The key principle:

Tissue diagnosis is NOT mandatory if the tumour is potentially resectable [4]. A resectable tumour on imaging should be resected regardless of biopsy result (a negative biopsy does not exclude malignancy; a biopsy delay could allow progression to unresectable disease).

Tissue diagnosis IS required when [4]:

  • CT failed to demonstrate typical features of the suspected malignancy
  • Before chemotherapy (oncologists need a pathological diagnosis to select regimen)
  • Suspected secondary metastasis to pancreas (e.g., from RCC, lung, breast — different treatment)
  • Uncertain diagnosis where management would change based on histology (e.g., IgG4-related disease vs cholangiocarcinoma)

Methods of tissue diagnosis:

MethodPreferred ForNotes
EUS-guided FNAC/biopsyPancreatic massesPreferred over percutaneous approach (↓tumour seeding risk) [4]
ERCP brush cytology/biopsyBile duct stricturesSensitivity ~60% only [12]; can also relieve jaundice by placing temporary stent simultaneously [4]
CT-guided percutaneous biopsyDeep liver lesions, lymph nodesHigher risk of tumour seeding along needle tract
Choledochoscopy (SpyGlass) with targeted biopsyIndeterminate bile duct stricturesHigher sensitivity than brush cytology
OGD with biopsyCA ampulla, CA duodenumDirect visualisation and biopsy of luminal lesion

ScenarioFirst-line IxNext StepKey Points
Suspected stone disease (young, painful, fluctuating jaundice)USG → LFT, CBC, amylaseLow risk: MRCP; High risk/cholangitis: ERCPUSG sees GB stones but misses 2/3 of CBD stones [2]
Suspected MBO (elderly, painless, progressive jaundice)CT abdomen with pancreatic protocol (can skip USG) [3][10][12]EUS ± FNAC; Staging CT TAP / PET-CT; Staging laparoscopyDo CT before ERCP — stenting obscures tumour assessment [12]
Acute cholangitisUSG (rapid, bedside) + Bloods (CBC, LFT, CRP, Blood C/ST)Emergency ERCP drainage (or PTBD if ERCP fails)Management of sepsis is priority #1 [3][10]
Uncertain cause (equivocal LFT, mild jaundice)USG → MRCPCT if mass identified; ERCP if stone/stricture on MRCPMRCP is the non-invasive bridge between USG and intervention
Known malignancy — assessing resectabilityTriphasic CT + EUS + PET-CTStaging laparoscopy pre-operativelyResectability criteria: vascular encasement, distant mets, bilateral biliary involvement [4][6]

High Yield Summary — Diagnosis

  1. Cholestatic LFT pattern: ↑↑↑ALP/GGT >> AST/ALT; ↑conjugated bilirubin; albumin initially normal. More pronounced in malignancy than in stone disease.

  2. USG is first-line: confirms dilated ducts (extrahepatic cholestasis). CBD > 8 mm is pathological. Limitation: cannot see distal CBD/ampulla/pancreas due to bowel gas.

  3. CT abdomen with pancreatic protocol: workhorse for MBO diagnosis + staging. Key findings: double duct sign, hypoenhancing pancreatic mass, vascular encasement. Do CT before ERCP (stenting obscures tumour).

  4. MRCP: non-invasive cholangiogram; has largely replaced ERCP as a diagnostic tool. Use when intervention is unlikely.

  5. ERCP: gold standard for direct cholangiography; both diagnostic and therapeutic. Reserve for when drainage/stenting is needed. Complications: pancreatitis, perforation, bleeding.

  6. PTC/PTBD: alternative when ERCP fails or is contraindicated; preferred for proximal (hilar) tumours. Acute complications (5–10%): bleeding (most common), sepsis.

  7. EUS-guided FNAC: preferred method for tissue diagnosis of pancreatic masses (↓tumour seeding vs percutaneous). Not useful for CA ampulla or CA duodenum (use OGD + biopsy instead).

  8. Tissue diagnosis is NOT mandatory for potentially resectable tumours.

  9. Tumour markers: CA 19-9 unreliable in cholestasis (take after drainage); CEA non-specific; AFP > 400 = HCC. Absence of elevated markers does NOT exclude malignancy.

  10. Goals of imaging: (1) extrahepatic vs intrahepatic, (2) level of obstruction, (3) exact cause, (4) cancer staging.


Active Recall - Diagnosis of Obstructive Jaundice


[1] Senior notes: felixlai.md (Malignant biliary obstruction diagnosis, Acute cholangitis diagnosis, Cholangiocarcinoma diagnosis sections) [2] Senior notes: maxim.md (Obstructive jaundice section 5.3, Choledocholithiasis investigations, Cholangiocarcinoma investigations) [3] Senior notes: Ryan Ho GI.pdf (Section 4.1.2 Malignant Biliary Obstruction p194–196, Approach to Jaundice p192–193) [4] Senior notes: maxim.md (Pancreatic carcinoma investigations section) [6] Senior notes: maxim.md (Cholangiocarcinoma investigations — cholangiography: ERCP for distal, PTC for proximal; staging) [7] Senior notes: felixlai.md (Cholangiocarcinoma biochemical tests p548–549) [10] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.3.10 Malignant Biliary Obstruction p297–299, Courvoisier's law, tumour markers caution) [12] Senior notes: Ryan Ho Fundamentals.pdf (CT abdomen pancreas protocol p299); Senior notes: Ryan Ho GI.pdf (CT findings p196, ERCP indications p196) [13] Senior notes: Ryan Ho Fundamentals.pdf (Physical examination p296, Clotting profile interpretation); Senior notes: Ryan Ho GI.pdf (p193) [14] Senior notes: Ryan Ho Fundamentals.pdf (Evaluation of ↑ALP p307) [16] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p34 — Imaging modalities) [17] Senior notes: Ryan Ho Diagnostic Radiology.pdf (PTBD p82) [18] Senior notes: Ryan Ho Diagnostic Radiology.pdf (Cholangiogram p22 — contraindication: biliary sepsis)

The management of obstructive jaundice is driven by two parallel questions that must be answered simultaneously [1][3][10]:

  1. What is the patient's general status? (Can they tolerate surgery?)
  2. What is the tumour/disease status? (Is it benign or malignant? If malignant, is it resectable?)

The four management priorities, in order [19]:

  1. Establish diagnosis
  2. Delineate level and cause of obstruction
  3. Treat suppurative cholangitis (if present — this kills first)
  4. Definitive treatment

This seemingly simple list drives every decision. Let me walk you through the logic.



Management of biliary sepsis is the FIRST priority → it can quickly kill! [3][10]

Acute Cholangitis Management (RAD — must know!) [20]

The mnemonic RAD captures the three pillars:

  • R = Resuscitation
  • A = Antibiotics
  • D = Drainage

R — Resuscitation

  • Recognise signs of shock: hypotension, oliguria, altered mental status, cold and clammy skin, metabolic acidosis [1]
  • IV fluid resuscitation to maintain organ perfusion and prevent multiorgan failure
  • Continuous monitoring of vitals to detect failure of conservative treatment: ↑temperature/pulse, ↓BP/consciousness/urine output, increased abdominal tenderness [1]

A — Antibiotics

  • Empirical antibiotics started immediately after blood cultures are drawn [20]:
    • Augmentin (amoxicillin-clavulanate) — covers Gram-negatives + anaerobes
    • OR Unasyn (ampicillin-sulbactam)
    • OR Cefuroxime (Zinacef) + Metronidazole (Flagyl) [1][3]
  • 70–80% of patients should respond to initial antibiotic therapy within ≤24 hours [3]
  • Target organisms: E. coli, Klebsiella pneumoniae, Enterococcus sp., Enterobacter sp., Bacteroides fragilis [1]; add Pseudomonas cover if stent is present [20]

D — Drainage (The Most Important Intervention)

Urgent biliary drainage is the single most important intervention in acute cholangitis [3]. Why? Because if biliary drainage is not relieved, antibiotics cannot be excreted into the biliary tract and therefore cannot eradicate the infection [3] — the infected bile remains a sealed abscess.

Timing [3]:

  • Mild/moderate cholangitis: drainage within 24–48 hours
  • Severe cholangitis (organ dysfunction) or no response to antibiotics: drainage within 24 hours

Choice of drainage procedure [1][3][20][21]:

First-line: ERCP → Second-line: Percutaneous (PTBD) → Third-line: Surgical drainage

This is the QMH practice: ERCP → PTBD → ECBD (exploration of CBD) [1].

ModalityDetails
ERCP (1st line)Associated with significantly ↓mortality/morbidity (4.7–10% vs 10–50% with surgery) and 90–95% rate of successful stone removal [3]. Sphincterotomy + stone extraction or stent placement.
PTBD (2nd line)If ERCP fails or is contraindicated. Requires dilated biliary system. More invasive than ERCP [1].
Surgical drainage (3rd line)Open/laparoscopic exploration of CBD ± T-tube drainage. Only if ERCP and PTBD both fail [1].

Relative contraindications for ERCP [1][21]:

  • Altered GI anatomy: Billroth II gastrectomy, Roux-en-Y anastomosis (the duodenoscope cannot reach the papilla in the normal way)
  • Structural upper GI abnormalities (oesophageal diverticulum, stricture, gastric volvulus, GOO) [1]
  • Unstable cardiopulmonary disease
  • Known or suspected perforation

ERCP complications [21]:

  • Perforation
  • Bleeding from papillotomy (sphincterotomy)
  • Pancreatitis (most common significant complication, ~3–5%)

Key Principle — Definitive Treatment Deferred

Definitive treatment should be deferred until cholangitis has been treated and the proper diagnosis is established [1]. Do NOT rush a patient with active cholangitis to the operating theatre for a Whipple procedure. Stabilise first, drain, investigate, then plan definitive surgery.


Part 2: Management of Benign Causes (CBD Stones)

ERCP with sphincterotomy + CBD stone removal is the standard of care [2]:

  • Sphincterotomy: electrocautery incision of the sphincter of Oddi to widen the papillary opening
  • Methods of stone removal [2]:
    • Wire baskets (Dormia basket)
    • Stone extraction balloon
    • Mechanical lithotripsy (for large stones that cannot be extracted whole)

Indicated if ERCP is contraindicated (e.g., altered anatomy) [2]:

  • Approaches:
    • Transcystic (1st line): catheter via cystic duct → cholangiogram → balloon extraction
    • Choledochotomy (2nd line): incise CBD → remove stones → choledochoscopy to confirm clearance
    • Percutaneous choledochoscopy
  • Advantage: can be performed as one-stage surgery together with laparoscopic cholecystectomy [2]
  • After exploration: T-tube may be inserted for subsequent cholangiogram and bile drainage, but T-tubes are shown to increase complications (infection, bile leak, tube dislodgement) → primary closure preferred if existing biliary stent [2]

  • Elective laparoscopic cholecystectomy after stone clearance — still ~5% risk of recurrent biliary events (residual/dropped stones, primary RPC stones) [2]
  • Recommended within 2–6 weeks of ERCP stone clearance

Part 3: Management of Malignant Biliary Obstruction (MBO)

This is the most complex and clinically important section. The decision tree hinges on two assessments [1]:

Assessment of patient status (good/bad) [1]:

  • Age and concomitant medical illness
  • Hidden medical illness: CXR, ECG, spirometry
  • Nutrition: LFT (albumin)
  • Fluid and electrolytes: RFT
  • Coagulopathy: CBC, clotting profile

Assessment of tumour status (confined/spread) [1]:

Clinical signs of inoperability [1]:

  • Irregular surface hepatomegaly (liver metastases)
  • Troisier's sign (Virchow's node) — left supraclavicular LN
  • Blumer's shelf — peritoneal metastasis palpable on DRE
  • Sister Mary Joseph nodules — periumbilical metastatic nodule
  • Ascites — peritoneal metastasis

Radiological signs of inoperability [1]:

  • LN metastasis (retropancreatic, paracoeliac, paraaortic)
  • Distant metastasis (lung, peritoneum, liver)
  • Arterial involvement: SMA, coeliac axis (encasement > 180° is absolute contraindication) [4]
  • Venous involvement: SMV, portal vein
    • Portal vein involvement is NOT an absolute contraindication [1] — venous resection with reconstruction is appropriate to improve resectability and achieve R0 resection (absence of microscopic residual tumour). QMH may consider resection of portal vein depending on the extent of involvement [1]
    • However, unreconstructible SMV/portal vein involvement (no suitable vessel proximal and distal for interposition graft) IS an absolute contraindication [4]

Unresectability criteria (for cholangiocarcinoma) [6][22]:

  • Invasion of major vessels (main PV, main hepatic artery, coeliac trunk, SMA, SMV)
  • Extensive involvement of biliary tree (bilaterally > 2° radicles)
  • LN metastasis beyond regional nodes (retropancreatic, paracoeliac, paraaortic)
  • Distal organ metastasis (lung, peritoneum)
  • Inadequate liver remnant if hepatectomy is required [22]

The flowchart from lecture [1]:

Patient StatusTumour StatusAction
BadAnyPTBD or endoprosthesis (palliative)
GoodSpreadPTBD or endoprosthesis (palliative)
GoodConfinedLaparotomy → if confirmed confined at surgery → radical resection (best); if spread found → bypass

No promise of resection until laparotomy findings document absence of spread [1]. Look for peritoneal nodules after laparotomy before resection → send for frozen section to rule out malignancy if suspicious [1].


C. Pre-operative Optimisation

Reasons why MBO is high risk for operation and measures to reduce complications [1]:

ProblemMechanismIntervention
Cancer cachexia → MalnutritionTumour cytokines, anorexia, fat malabsorptionNutritional support (enteral preferred)
Liver derangement → Bleeding tendencyVitamin K malabsorption + impaired synthesisIV Vitamin K + FFP during surgery
Superimposed biliary infectionStagnant bile → bacterial overgrowthAntibiotic cover
Renal impairmentBilirubin nephrotoxicity, endotoxaemiaAdequate hydration, monitor RFT

This is a nuanced and frequently examined topic [1][22]:

Target level: Serum bilirubin < 50 µmol/L (or < 20 µmol/L if concomitant partial hepatectomy is needed) [22]

Theoretically: Do NOT need to drain if no sepsis + early surgery can be offered within 1–2 weeks [1]

  • Pre-operative biliary drainage increases risk of serious complications even in expert hands
  • But surgical-related complications are comparable even without drainage

Practically (QMH): Drain ALL patients since QMH cannot offer early surgery [1]

  • Whipple operation has to wait 6–8 weeks → the chance of biliary sepsis is very high without drainage while waiting [1]

Advantages of pre-operative drainage [1]:

  • Minimise risk of developing cholangitis
  • Relieve jaundice and pruritus, prevent complications of cholestasis
  • Allow time for neoadjuvant therapy in locally advanced CA head of pancreas

Disadvantages [1]:

  • Increase number of interventions and costs
  • Increase risk of procedure-related complications (cholangitis, pancreatitis, bleeding, perforation, blocked stent)
  • Biliary stenting interferes with tumour evaluation on CT [22]
  • Risk of needle tract seeding if PTBD is used [22]

Indications for pre-operative drainage [3][10][22]:

  • Biliary sepsis
  • Poor liver function especially if prolonged obstruction or partial hepatectomy needed
  • Klatskin tumour — drainage allows normalisation of liver function for pre-op ICG testing and post-op monitoring [3][10]
  • Need for evaluation of biliary anatomy

Pre-op Drainage — Theory vs HK Reality

In theory, if you could operate within 1–2 weeks, you wouldn't need to drain. But in HK, delayed drainage is often not realistic as patients need to wait months for OT [3]. So the practical answer at QMH is: drain everyone with MBO who is a surgical candidate, because the wait is too long to leave them obstructed.


D. Definitive Surgery — Site-Specific Resections

Surgical treatment is the only potentially curative treatment [1]. Unfortunately, only 15–20% of patients are surgical candidates due to late presentation [1].

Surgical treatment is directed at the underlying pathology [1]:

PathologyOperationKey Details
Periampullary carcinoma (CA head of pancreas, CA ampulla, distal cholangioCA)Whipple operation (pancreaticoduodenectomy)PPPD (pylorus-preserving pancreaticoduodenectomy) can be considered provided R0 resection achievable — shorter operative time, less blood loss, improved post-op nutrition, lower dumping/marginal ulcer/bile reflux gastritis [1]
CA gallbladderRadical cholecystectomyRemoval of tumour + part of liver (segments 4b and 5) + draining LNs [1]. T1a = simple cholecystectomy; T1b/T2 = extended cholecystectomy [1]
Klatskin tumour (perihilar cholangioCA)Major hepatectomy + Caudate lobectomy + extrahepatic bile duct resection + portal LN dissection + reconstruction (Roux-en-Y hepaticojejunostomy) [1][6]Extent depends on Bismuth-Corlette type
Intrahepatic cholangioCAPartial hepatectomy + portal LN dissection [6]
Distal cholangioCAPancreaticoduodenectomy (Whipple) [22]Similar to CA head of pancreas
RPCHepatobiliary resection + biliary-enteric anastomosis (hepaticojejunostomy)Resect areas of recurrent infection, biliary stasis, hepatic atrophy [1][23]

"Whipple" = pancreaticoduodenectomy (named after Allen Whipple). It removes:

  • Head of pancreas
  • Duodenum (D1–D4)
  • Distal stomach (classic) or preserves pylorus (PPPD)
  • Gallbladder
  • Distal CBD
  • Regional lymph nodes

Then reconstructs with three anastomoses:

  1. Pancreaticojejunostomy (or pancreaticogastrostomy) — reconnects pancreatic remnant to jejunum
  2. Hepaticojejunostomy — reconnects bile duct to jejunum
  3. Gastrojejunostomy (or duodenojejunostomy in PPPD) — reconnects stomach to jejunum

Adjuvant chemotherapy is indicated for ALL resected CA pancreas [4]:

  • Start within 12 weeks post-op [4]
  • FOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) — current first-line adjuvant [3][4]
  • Gemcitabine + capecitabine × 6 months — alternative regimen [4]

For cholangiocarcinoma: adjuvant chemotherapy has survival advantage [7]:

  • Gemcitabine, capecitabine, leucovorin-modulated fluorouracil (5-FU) [7]

E. Palliative Management

For the majority of patients (80–85%) who are not surgical candidates, palliation is the goal. The three main indications for palliation [1]:

1. Relief of Obstructive Jaundice — Stenting

ERCP with endoprosthesis (endoscopic stenting) is ALWAYS first-line regardless of level of obstruction, especially for periampullary carcinoma [1], except when:

  • Contraindications for ERCP (altered anatomy, structural upper GI abnormalities) [1]
  • Multiple stenting required or difficulty reaching intrahepatic bile ducts [1]

ERCP with endoprosthesis is preferred over PTBD [1] because:

  • PTBD is technically more difficult
  • Bleeding is common with PTBD due to puncture of hepatic artery or portal vein before reaching the bile duct (portal triad) [1]
  • If PTBD bleeding occurs [1]:
    • Stabilise and resuscitate
    • Clamp the PTBD catheter
    • Perform cholangiogram by injecting contrast into PTBD to delineate whether catheter is in hepatic artery or portal vein
    • Remove catheter slowly to control bleeding — do NOT remove immediately (converts to free haemoperitoneum)

However, for hilar obstruction: PTBD has a higher success rate for palliation of jaundice + ↓early cholangitis but ERCP offers initial internal drainage → ERCP is usually attempted first [22]

FeaturePlastic StentMetallic Stent (SEMS)
CostCheapExpensive
PatencyShorter (~2–5 months) → requires frequent exchanges [22]Longer (≥270 days) [22]
RemovabilityEasily exchangedCannot be removed
PreferenceIf diagnosis uncertain, or as temporary bridge to surgeryPreferred if confirmed inoperable — more durable [1]
Covered vs uncovered—Uncovered preferred (no difference in patency, ↓risk of occlusion of branches of biliary system) [22]

Complications of biliary stenting [1][22]:

  • Stent occlusion (most common): sludge (most common cause), tumour ingrowth, tumour overgrowth [22]
  • Stent migration
  • Cholangitis / cholecystitis

For Bismuth Type II–IV tumours [22]:

  • Only 25–30% of liver needs to be drained to relieve jaundice → unilateral drainage is theoretically sufficient
  • However, bilateral stents offer complete drainage with ↓risk of biliary sepsis → usually still preferred

Performed only when the tumour is found unresectable intra-operatively (during what was planned as a curative laparotomy) [3][4]:

Double bypass (if jaundice + GOO) [3]:

  • Biliary bypass: hepaticojejunostomy (HJ) — anastomosis of jejunum to CHD; or choledochojejunostomy (CJ) — anastomosis of jejunum to CBD
    • Choledochoduodenostomy is NOT advised because of proximity of the duodenum to the tumour [1]
  • Gastric bypass: gastrojejunostomy (GJ) — for gastric outlet obstruction
  • Jejunojejunostomy (JJ) — as part of Roux-en-Y reconstruction
  • Also: obtain transduodenal trucut biopsy ± celiac plexus block during the same operation [4]

Triple bypass: HJ/CJ + GJ + JJ [3]

If found unresectable on imaging (never goes to OT) [4]:

  • ERCP stenting (SEMS preferred): biliary stent ± duodenal stent
  • PTBD if unfit for ERCP
  • Systemic chemotherapy after obtaining tissue diagnosis (EUS-guided biopsy)

  • Narcotics (opioids) — e.g., morphine, as per WHO analgesic ladder [1]
  • Celiac plexus block (celiac plexus neurolysis): endoscopic USG-guided or CT-guided injection of alcohol/phenol into the celiac plexus [1] — interrupts pain transmission from the retroperitoneal tumour via the splanchnic nerves. Very effective for the classic dull, boring epigastric pain radiating to the back
  • Short-course radiotherapy for pain

  • Endoscopic duodenal wall stenting (SEMS) — first-line in non-operative patients
  • PEG (percutaneous endoscopic gastrostomy) placement for decompression in patients unfit for stenting [1]
  • Gastrojejunostomy — surgical bypass (if patient goes to OT for planned resection and is found unresectable) [1]

For CA pancreas [1][3]:

  • First-line: FOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin)
  • Gemcitabine monotherapy (if unfit for FOLFIRINOX)
  • Gemcitabine results in symptomatic improvement, improved pain control, performance status and weight gain in unresectable pancreatic cancer [1]
  • Neoadjuvant chemoradiotherapy: to downstage patients with borderline resectable disease [1]

For cholangiocarcinoma [7][22]:

  • Intrahepatic: prefer 5-FU-based chemoirradiation; local options include RFA, TACE, intra-arterial embolization, radioembolization [22]
  • Extrahepatic: prefer fluoropyrimidine-based chemoirradiation; local options include photodynamic therapy [7][22]
  • Photodynamic therapy (PDT): IV porphyrin photosensitiser → endoscopic application of specific-wavelength light to tumour bed [7]

  • Exocrine insufficiency: pancreatic enzyme replacement therapy (PERT — e.g., Creon)
  • Endocrine insufficiency: oral hypoglycaemics (OHA) or insulin for new-onset diabetes [4]

Part 4: Management of Specific Benign Conditions

Acute management [20][23]:

  • Resuscitation + antibiotics + biliary drainage (ERCP difficult for intrahepatic stones → PTBD or T-tube drainage or hepaticocutaneojejunostomy (HCJ) preferred) [20]

Long-term management [23]:

  • Regular ductal clearance: USG surveillance, ERCP for stone retrieval / stricture dilatation
  • Hepatobiliary resection + biliary-enteric anastomosis (hepaticojejunostomy): resect areas of recurrent infection, biliary stasis, and hepatic atrophy [1]
    • Indication: atrophic liver segment, failed non-operative treatment, suspected cholangioCA [20]
    • Hepaticojejunostomy is frequently required; standard biliary drainage procedures (choledochoduodenostomy or choledochojejunostomy) are contraindicated since residual strictured segments may not drain adequately [1]
    • May include cutaneous stoma for future percutaneous choledochoscopy access [23]
  • Surveillance for cholangioCA: clinical deterioration, unexplained ↑cholestasis measures; consider routine cytology brushing during ERCP [23]

  • Dominant strictures: ERCP balloon dilatation ± short-term stenting
  • Cholangitis episodes: antibiotics + drainage
  • Medical therapy: ursodeoxycholic acid (UDCA) — evidence debated; may improve biochemistry but uncertain effect on disease progression
  • Liver transplantation: definitive treatment for end-stage PSC

ScenarioFirst-lineSurgical OptionKey Points
Acute cholangitisRAD: Resuscitate + Abx + ERCP drainagePTBD → Surgical if both failDrainage is the most important intervention
CBD stone (no sepsis)ERCP sphincterotomy + stone removalSurgical CBD exploration if ERCP failsElective cholecystectomy after clearance
Resectable MBOPre-op drainage (bilirubin < 50) → Staging laparoscopy → Radical resectionWhipple / hepatectomy / radical cholecystectomy (site-specific)Adjuvant chemo for ALL resected CA pancreas
Unresectable MBO (found on imaging)ERCP stenting (SEMS) + tissue Dx + chemo—Palliative intent only
Unresectable MBO (found intra-op)—Double/triple bypass + celiac plexus block + biopsyTake biopsy during the same operation
RPCAcute: Abx + PTBD/ERCP; Long-term: ductal clearanceHepatobiliary resection + hepaticojejunostomySurveillance for cholangioCA (10% develop it)
Pain (CA pancreas)Opioids → celiac plexus block—EUS-guided or CT-guided celiac plexus neurolysis
GOOEndoscopic duodenal stentGastrojejunostomyPEG for decompression if unfit

High Yield Summary — Management

  1. RAD for acute cholangitis: Resuscitate, Antibiotics (Augmentin or Cefuroxime + Flagyl), Drainage (ERCP 1st line → PTBD → surgical). 70–80% respond to antibiotics within 24h; 15% need emergency drainage.

  2. ERCP with endoprosthesis is ALWAYS 1st line for palliative stenting — except altered anatomy or need for multiple intrahepatic stents → then PTBD.

  3. Metallic stent preferred if confirmed inoperable (longer patency ≥270 days vs 2–5 months for plastic).

  4. Pre-operative biliary drainage: target bilirubin < 50 µmol/L. Theoretically not needed if surgery within 1–2 weeks, but practically at QMH drain ALL patients (6–8 week surgical wait).

  5. Radical resection is the only curative option: Whipple (periampullary), radical cholecystectomy (CA GB), major hepatectomy + caudate lobectomy (Klatskin), partial hepatectomy (intrahepatic cholangioCA).

  6. Only 15–20% of MBO patients are surgical candidates due to late presentation.

  7. Adjuvant chemo for ALL resected CA pancreas: FOLFIRINOX or gemcitabine + capecitabine, start within 12 weeks.

  8. Portal vein involvement is NOT an absolute contraindication to surgery — venous resection/reconstruction can achieve R0.

  9. Palliative triple bypass (HJ + GJ + JJ) if found unresectable intra-operatively with jaundice + GOO.

  10. Celiac plexus block for intractable pain in CA pancreas (EUS or CT-guided).


Active Recall - Management of Obstructive Jaundice


[1] Senior notes: felixlai.md (MBO treatment sections p503–506, Acute cholangitis treatment p522, RPC treatment p527, Cholangiocarcinoma treatment p551, CA gallbladder treatment p569–570, CA pancreas treatment p596–597) [2] Senior notes: maxim.md (Choledocholithiasis management section) [3] Senior notes: Ryan Ho GI.pdf (Section 4.1.2 Approach to evaluation and management p195, Acute cholangitis Mx p256, CA pancreas management p356) [4] Senior notes: maxim.md (Pancreatic carcinoma resectability criteria, curative and palliative treatment sections) [6] Senior notes: maxim.md (Cholangiocarcinoma management — unresectability criteria, surgical approach) [7] Senior notes: felixlai.md (Cholangiocarcinoma palliation and chemotherapy p551) [10] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.3.10 Approach to evaluation and management p298) [17] Senior notes: Ryan Ho Diagnostic Radiology.pdf (PTBD p82) [19] Lecture slides: Malignant biliary obstruction.pdf (p15 — Management priorities) [20] Senior notes: maxim.md (Acute cholangitis acute management RAD, RPC management) [21] Lecture slides: GC 200. RUQ pain, jaundice and fever Cholecytitis and cholangitis Imaging of GI system.pdf (p14 — ERCP first line, complications, relative contraindications) [22] Senior notes: Ryan Ho GI.pdf (Section 4.3.3 Cholangiocarcinoma pre-op drainage p277, palliation of obstructive jaundice p278, unresectability criteria p276, surgical resection p277) [23] Senior notes: Ryan Ho GI.pdf (RPC management p258)

Obstructive jaundice is not simply a cosmetic problem — it sets off a cascade of systemic pathophysiological disturbances that, if unrelieved, lead to life-threatening complications. These complications can be organised into three broad categories: (A) complications of the obstruction itself, (B) complications of the underlying disease, and (C) complications of the treatment/intervention. Each is explained from first principles.


A. Complications of Biliary Obstruction Per Se

These are the systemic consequences of bile not reaching the gut and bilirubin/bile salts accumulating in the blood. They are common to all causes of obstructive jaundice and are the reason why MBO is high-risk for surgery [1][3][10].

Why does this happen?

Bile is normally sterile. However, when the biliary tree is obstructed, the flushing action of bile ceases → bile stasis → bacteria ascend from the duodenum or enter via the portal venous system → colonise the stagnant bile → overwhelming infection within a closed space [1][24].

  • Combination of biliary obstruction and significant bacterial contamination is required for cholangitis — obstruction without bacteria = obstructive jaundice; obstruction with bacterial overgrowth = acute cholangitis [1]
  • Normal barrier mechanisms are disrupted by obstruction: continuous flushing, bacteriostatic bile salts, biliary mucous IgA, and sphincter of Oddi all fail [1]
  • After endoscopic sphincterotomy, biliary stent insertion, or choledochal surgery, the barrier is permanently disrupted → these patients are at perpetually higher risk of cholangitis [1]
  • Foreign body (stent) serves as a nidus for bacterial colonisation [1]

Organisms: E. coli, Klebsiella pneumoniae, Enterococcus sp., Enterobacter sp., Bacteroides fragilis [1]

Clinical presentation:

  • Charcot's triad (present in 2/3): fever + RUQ pain + jaundice [1]
  • Reynold's pentad (present in < 10%): adds hypotension + altered mental status — indicates suppurative cholangitis with septic shock progressing to multiorgan failure [1]

Why is it so dangerous? The biliary system drains into the portal venous system → bacteria and endotoxins have direct access to the systemic circulation → bacteraemia → septic shock → multiorgan failure if not drained urgently. If biliary drainage is not relieved, antibiotics cannot be excreted into the biliary tract and cannot eradicate the infection [3] — the infected bile acts as an undrained abscess.

Cholangitis — The Complication That Kills First

Management of biliary sepsis is the FIRST priority in obstructive jaundice → it can quickly kill! [3][10]. A patient with MBO can survive weeks to months with jaundice alone, but untreated cholangitis can kill in hours to days.

Why does obstruction cause bleeding?

The mechanism is twofold [1]:

  1. Vitamin K malabsorption: Bile salts are essential for emulsification and absorption of dietary fats, including fat-soluble vitamin K. No bile in the gut → no fat emulsification → vitamin K is not absorbed → the liver cannot synthesise vitamin K-dependent clotting factors II, VII, IX, X (and proteins C and S) → ↑PT/INR → coagulopathy [1][3][10]

  2. Impaired clotting factor synthesis: In prolonged obstruction, cholestasis-induced hepatocyte damage impairs the liver's synthetic capacity directly, compounding the vitamin K deficiency [1]

Clinical significance: Patients may present with easy bruising, petechiae, prolonged bleeding from venepuncture sites, or frank haemorrhage. This is critical pre-operatively — IV vitamin K and FFP must be given during surgery to correct the coagulopathy [1].

A key clinical test: ↑INR may be due to hepatocellular dysfunction (unresponsive to vitamin K) or cholestasis (responsive to IV vitamin K) [13]. If parenteral vitamin K corrects the INR within 24–48 hours, the coagulopathy is from malabsorption (obstructive) — a reassuring sign that the liver's synthetic machinery is intact.

Why does this happen?

Without bile salts in the gut lumen, fat cannot be emulsified into micelles → fat is not absorbed → passes through as steatorrhoea (fatty, loose, floating, foul-smelling stools) [3][10][13].

Vitamin deficiency (A, D, E, K) — all fat-soluble vitamins are malabsorbed [3][10][13]:

VitaminConsequence of Deficiency
ANight blindness, dry eyes (xerophthalmia)
DHepatic osteodystrophy — osteopenia, osteoporosis, rarely osteomalacia; reflects inhibitory effect of retained toxin on osteoblasts [25]
EPeripheral neuropathy, haemolytic anaemia (rare)
KCoagulopathy (see above) — the most clinically important deficiency

In chronic obstruction (e.g., PSC), vitamin A and D deficiency are more common and require supplementation [25].

Why are obstructed patients prone to infection?

This goes beyond cholangitis. Obstructive jaundice causes generalised immune suppression through several mechanisms [1]:

  • Endotoxaemia: The liver's Kupffer cells (resident macrophages of the reticuloendothelial system) normally clear endotoxins absorbed from the gut via the portal vein. In cholestasis, Kupffer cell function is impaired → endotoxins escape into the systemic circulation → trigger systemic inflammatory response [1]
  • Impaired reticuloendothelial function: Beyond Kupffer cells, the entire reticuloendothelial system (spleen, lymph nodes) is depressed [1]
  • Impaired cell-mediated immunity: T-cell function and neutrophil phagocytosis are suppressed by accumulated bile salts and bilirubin [1]
  • Absent bile salts in gut → bacterial overgrowth → increased bacterial translocation across the gut mucosa

Clinical relevance: Patients with MBO are at significantly increased risk of post-operative sepsis, wound infection, and pneumonia. Perioperative antibiotic prophylaxis is essential.

Why? [1]

  • Impaired protein synthesis by the cholestatic liver → inadequate collagen deposition and tissue repair
  • Malnutrition (cancer cachexia + fat malabsorption) → protein-calorie deficit
  • Immune dysfunction (see above) → impaired inflammatory response needed for wound healing

Studies from the 1980s showed that jaundiced patients had higher rates of anastomotic leak, haemorrhage, and renal failure [19]. This is the historical rationale for pre-operative biliary drainage.

Why?

Multiple mechanisms converge to damage the kidneys in obstructive jaundice:

  • Bilirubin and bile salts are directly nephrotoxic — they deposit in renal tubules and cause tubular injury
  • Endotoxaemia promotes renal vasoconstriction (similar mechanism to hepatorenal syndrome in cirrhosis)
  • Dehydration from anorexia, vomiting, and bile losses (if external PTBD drainage)
  • Contrast nephropathy from CT contrast or cholangiographic contrast during investigation

In prolonged or chronic obstruction [3][10][13]:

  • Liver decompensation: encephalopathy, hepatic fetor, worsening ascites [3][13]
  • Mechanism: prolonged cholestasis → secondary biliary cirrhosis → portal hypertension → hepatic synthetic failure
  • This is a late complication but is the eventual endpoint if obstruction is not relieved

Due to stone disease [3][13] — a CBD stone impacted at the ampulla of Vater obstructs both the bile duct AND the pancreatic duct → reflux of bile into the pancreatic duct → premature activation of pancreatic enzymes within the gland → autodigestion → acute pancreatitis.

  • Presents with abdominal pain radiating to the back with nausea and vomiting [13]
  • Gallstone pancreatitis is one of the two most common complications of CBD stones (the other being cholangitis) [1]

B. Complications of the Underlying Disease

ComplicationMechanism
Tumour progression / metastasisLocal invasion (SMA, PV, coeliac axis), liver mets, peritoneal mets, lung mets — the natural history of untreated malignancy
Gastric outlet obstruction (GOO)CA head of pancreas or periampullary tumour grows to obstruct the duodenum in addition to the bile duct [1]
Trousseau syndromePancreatic CA → hypercoagulable state (tumour-derived tissue factor and mucin) → migratory superficial thrombophlebitis
New-onset diabetes mellitusCA pancreas destroys islets of Langerhans → endocrine insufficiency
Exocrine insufficiencyTumour obstructs the pancreatic duct → pancreatic juice cannot reach the duodenum → maldigestion of fats and proteins → steatorrhoea, weight loss

ComplicationMechanism
Biliary sepsisRecurrent cholangitis from intrahepatic stone disease
PancreatitisResult of passage of biliary stones through the ampulla [24]
Liver abscessAscending infection from infected bile ducts → abscess at liver and distant sites including lungs and brain [24]
RuptureRupture of obstructed pus-filled bile ducts into peritoneum → biliary peritonitis [24]
FistulisationFormation of choledocho-duodenal fistula into GI tract or abdominal wall [24]
Secondary biliary cirrhosisChronic biliary obstruction → progressive fibrosis → cirrhosis → portal hypertension → liver failure [24][26]
Portal vein thrombosisChronic peri-portal inflammation → venous thrombosis [24]
CholangiocarcinomaChronic inflammation → malignant transformation of bile duct epithelium; 10% of RPC patients develop cholangioCA [24][26]

ComplicationMechanism
Biliary stricturesUp to 60% of patients develop a dominant stricture in intra-/extrahepatic biliary tree [25]
CholangitisDevelops spontaneously in patients with bile duct stones, obstructing strictures, or after endoscopic/surgical manipulation [25]
Choledocholithiasis and cholelithiasisDue to cholesterol or pigment stones from biliary stasis [25]
CholangiocarcinomaHigh incidence (lifetime risk 5–15%); necessitates screening including USG or MRCP with measurement of serum CA 19-9 [25]
Gallbladder cancerIncreased risk in PSC patients [25]
Hepatocellular carcinomaPatients with PBC/PSC and cirrhosis are at increased risk [25]
Secondary biliary cirrhosis → liver failureEnd-stage complication; indication for liver transplantation [24]

C. Complications of Treatment / Interventions

ComplicationMechanismIncidence
Post-ERCP pancreatitisPapillary oedema from instrumentation → transient pancreatic duct obstruction → pancreatic enzyme activationMost common significant complication (~3–5%)
Bleeding (post-sphincterotomy)Arterial or venous bleeding from the cut sphincter~1–2%
PerforationDuodenal wall perforation by the endoscope or sphincterotome~0.5%
CholangitisIncomplete drainage after contrast injection into an obstructed system → bacterial overgrowth in residual bileVariable
BacteraemiaInstrumentation of infected bile ducts → bacteria enter bloodstream → antibiotic prophylaxis is required [2]Common (subclinical)

Acute complications (5–10%) [17]:

  • Bleeding into biliary system (most common) — puncture of hepatic artery or portal vein branches during needle insertion through the portal triad
  • Infection: septic shock — introduction of bacteria during the procedure
  • Pancreatitis (due to CBD damage — rare)
  • Puncturing other organs (e.g., lungs, kidneys) — the needle traverses the liver and can miss

Delayed complications (45–50%) [17]:

  • Biliary sepsis (cholangitis) — catheter acts as a foreign body and nidus for infection
  • Catheter migration — the external tube dislodges
  • Bile leak (→ peritoneal irritation, bile peritonitis)
  • Metastatic seeding — tumour cells spread along the needle tract (this is a real concern in malignancy)
  • Skin infection at the insertion site
  • Electrolyte and fluid loss — simple external PTBD causes loss of bile externally → dehydration, hyponatraemia, hypokalaemia, metabolic acidosis [1]

ComplicationMechanism
Stent occlusion (most common)Sludge (most common cause) — biofilm and biliary debris accumulate inside the stent lumen; tumour ingrowth — tumour grows through the stent mesh (uncovered metallic stents); tumour overgrowth — tumour extends beyond the stent ends [1][22]
Stent migrationStent shifts position → loss of drainage → recurrent jaundice/cholangitis
Cholangitis / cholecystitisStent acts as nidus for bacterial colonisation; cystic duct occlusion by stent → acute cholecystitis

Pre-operative biliary drainage has increased risk of serious complications [19]:

  • Pancreatitis (7%)
  • Cholangitis (26%)
  • Blocked stent (15%)
  • Bleeding (2%)
  • Perforation (2%)

However, surgery-related complications were comparable with or without drainage [19]. This is the core of the debate — routine pre-operative biliary drainage in patients undergoing surgery for CA pancreas increases rate of complications [19].

Jaundice itself causes coagulopathy, malabsorption, malnutrition and immune dysfunction; studies in the 1980s showed higher anastomotic leak, haemorrhage and renal failure in jaundiced patients [19]. But the drainage procedure introduces its own set of complications.

From prospective randomised trials [27]:

Surgical BypassStent / PTBD
Early morbidityHigher early morbidity, longer hospital stayLower initial mortality and morbidity
Long-term resultsBetter long-term resultsMore late biliary complications, more re-intervention (OR 7.23)

This means: stents are better for patients with short life expectancy (avoid major surgery), while surgical bypass is better for patients who might live longer (avoids repeated stent changes/blockages).

Early complications:

  • Intra-operative haemorrhage — the operation is adjacent to major vessels (SMA, PV, SMV)
  • Injury to adjacent organs (liver, kidneys, bowels)
  • Delayed gastric emptying (common) — the stomach loses its normal neural and hormonal coordination after the duodenum is removed
  • Pancreatitis
  • Pancreatic fistula (common) — leakage from the pancreaticojejunostomy; defined as drain amylase > 3× ULN after post-op day 3 [1]
  • Pancreatic anastomotic leak — the pancreaticojejunostomy is the "Achilles heel" of the Whipple (soft pancreas + narrow duct = highest risk)
  • Biliary anastomotic breakdown
  • Overall perioperative mortality: ~26–28% in older series (now ~2–5% in high-volume centres) [10]

Late complications:

  • Exocrine insufficiency → malabsorption and steatorrhoea (need lifelong PERT)
  • Endocrine insufficiency → diabetes mellitus (loss of islet mass)
  • Gastric stasis — particularly in patients undergoing pylorus-preserving Whipple's operation [1]
  • Marginal ulceration at the gastrojejunostomy
  • Dumping syndrome (more common with classic Whipple than PPPD)

D. Prognosis of Underlying Malignancy

Understanding prognosis contextualises the urgency and type of complications patients face [1]:

  • Highly lethal malignancy
  • 8% diagnosed when still localised; 27% when spread to regional LNs; 53% when already metastatic (majority) [1]
  • 5-year survival after pancreaticoduodenectomy: node-negative = 25–30%; node-positive = 10% [1]
  • Median survival for unresectable locally advanced disease = 12 months [1]
  • Median survival for metastatic disease to liver = 6 months [1]

  • Only ~20% operable at presentation [6][22]
  • Poor prognosis even after resection; adjuvant chemotherapy improves survival modestly

  • 10% disease-related mortality (7% secondary biliary cirrhosis, 3% cholangiocarcinoma) [26]
  • 10% concomitant cholangioCA at time of presentation [26]

CategoryComplicationMechanism
Obstruction itselfAcute cholangitis / biliary sepsisBile stasis + bacterial colonisation → infection in closed space
CoagulopathyVitamin K malabsorption + impaired hepatic synthesis
Fat malabsorption / steatorrhoeaNo bile salts → no fat emulsification
Fat-soluble vitamin deficiency (A, D, E, K)No bile salt-mediated absorption
Immune dysfunctionEndotoxaemia + impaired RES + impaired cell-mediated immunity
Poor wound/anastomotic healingImpaired protein synthesis + malnutrition
Renal failureBilirubin nephrotoxicity + endotoxaemia + dehydration
Liver decompensation / secondary biliary cirrhosisProlonged cholestasis → hepatocyte damage → fibrosis
Acute pancreatitisStone at ampulla obstructs pancreatic duct → autodigestion
Underlying diseaseTumour progression, GOO, metastasisNatural history of malignancy
Cholangiocarcinoma (in RPC, PSC)Chronic inflammation → malignant transformation
Cirrhosis (in RPC, PSC)Chronic biliary obstruction → fibrosis
TreatmentPost-ERCP pancreatitisPapillary oedema → transient pancreatic duct obstruction
PTBD bleeding, sepsis, catheter migrationPercutaneous needle injury; foreign body; displacement
Stent occlusion (sludge, tumour in/overgrowth)Biofilm, tumour encroachment
Pre-op drainage complicationsPancreatitis, cholangitis, stent block, bleeding, perforation
Whipple complicationsPancreatic fistula, DGE, anastomotic leak, exo/endocrine insufficiency

High Yield Summary — Complications

  1. Biliary sepsis (acute cholangitis) is the most immediately life-threatening complication — requires urgent ERCP drainage. Cholangitis needs BOTH obstruction AND bacterial contamination.

  2. Coagulopathy from vitamin K malabsorption is the most common haematological complication — always correct with IV vitamin K before invasive procedures. Test responsiveness to vitamin K to distinguish obstructive from hepatocellular coagulopathy.

  3. Immune dysfunction (endotoxaemia, impaired RES, impaired cell-mediated immunity) makes these patients highly susceptible to post-operative sepsis.

  4. Fat malabsorption → steatorrhoea + fat-soluble vitamin deficiency (A, D, E, K). Vitamin D deficiency → hepatic osteodystrophy.

  5. Secondary biliary cirrhosis is the end-stage of chronic unreleased obstruction → portal hypertension → liver failure.

  6. Pre-operative biliary drainage increases procedural complications (pancreatitis 7%, cholangitis 26%, stent block 15%) but surgery-related complications are comparable — the debate is about risk-benefit.

  7. Stent/PTBD: lower initial morbidity but more late complications and re-interventions (OR 7.23) vs surgical bypass: higher early morbidity but better long-term results.

  8. Whipple complications: pancreatic fistula and delayed gastric emptying are the most common post-operative problems. Perioperative mortality now ~2–5% at high-volume centres.

  9. RPC complications: biliary sepsis, liver abscess (may extend to lungs/brain), fistulisation, secondary biliary cirrhosis, cholangiocarcinoma (10%).

  10. CA pancreas prognosis: 53% present with metastatic disease; median survival 6 months if metastatic, 12 months if locally advanced unresectable.


Active Recall - Complications of Obstructive Jaundice


[1] Senior notes: felixlai.md (MBO pathophysiological disturbances p501, Acute cholangitis pathogenesis and complications p520–521, MBO surgical treatment and pre-op drainage p505–506, RPC complications p528, Gallstone complications p518–519, CA pancreas complications and prognosis p601–602) [2] Senior notes: maxim.md (ERCP complications — bacteraemia) [3] Senior notes: Ryan Ho GI.pdf (Section 4.1.2 Approach to evaluation and management p195, Complications of jaundice p193) [10] Senior notes: Ryan Ho Fundamentals.pdf (Section 3.3.10 Approach to evaluation and management p298, Perioperative Mx of MBO p303) [13] Senior notes: Ryan Ho Fundamentals.pdf (Complications p296 — liver decompensation, acute pancreatitis, fat malabsorption, coagulopathy) [17] Senior notes: Ryan Ho Diagnostic Radiology.pdf (PTBD acute and delayed complications p82) [19] Lecture slides: Malignant biliary obstruction.pdf (p24 — jaundice complications; p26 — pre-op drainage complications) [22] Senior notes: Ryan Ho GI.pdf (Section 4.3.3 Cholangiocarcinoma — palliation complications p278, pre-op drainage considerations p277) [24] Senior notes: felixlai.md (RPC complications p528, PSC overview p529) [25] Senior notes: felixlai.md (PSC specific complications p532 — biliary strictures, cholangitis, cholangiocarcinoma, gallbladder cancer, HCC, hepatic osteodystrophy) [26] Senior notes: Ryan Ho GI.pdf (RPC complications and prognosis p258); Senior notes: maxim.md (RPC complications) [27] Lecture slides: Malignant biliary obstruction.pdf (p35 — prospective randomised trials: surgical bypass vs stent/PTBD)

On this page

No Headings